Centre Publications

Research published by the Centre of Excellence- Treatable Traits investigators are highlighted below. These publications focus on articles that are directly relevant to Treatable Traits in chronic airway diseases.

2025

  1. AW Jones, VM McDonald, RF McLoughlin, TM Vella, AW Flynn, JD Blakey et al. Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma. Patient preference and adherence, 75-85. 2025.
  2. AT Burge, NS Cox, S Dal Corso, AW Jones, FM Faqih, AE Holland. Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 149-158, 2025.
  3. G Tikellis, AE Holland. Health disparities and associated social determinants of health in interstitial lung disease: a narrative review. European Respiratory Review 34 (176), 2025.
  4. M Graco, DJ Berlowitz, A Sawyer, AE Holland, KA Carey, Y Ahamed, et al. Polysomnographic titration of non-invasive ventilation in motor neurone disease (3TLA): protocol for a process evaluation of a clinical trial. Trials 26 (1), 79, 2025.
  5. LE Witjaksono, M Schulte, AE Holland, MS Wijsenbeek, YH Khor. Cough monitoring systems in adults with chronic respiratory diseases: a systematic review. European Respiratory Review 34 (175), 2025.
  6. Z Ahmadi, NE Smallwood, AM Russell, R Saggu, L Romero, AE Holland, et al. Supplemental oxygen for symptomatic relief in people with serious respiratory illness: a systematic review and meta-analysisEuropean Respiratory Review 34 (175), 2025.
  7. AT Burge, NS Cox, A Ponnudurai, AE Holland, J Bondarenko, CJ Hill, et al. Incidence of acute exacerbations of chronic respiratory disease during pulmonary rehabilitation delivered at home or hospital. ERJ Open Research 11 (1), 2025.
  8. AE Holland, C Bausewein, N Smallwood, M Ekström. Reply: A recommendation for increased airflow to relieve breathlessness: evidence in context is a strength of the GRADE approach. European Respiratory Journal 65 (2). 2025
  9. NS Cox, AE Holland. Pulmonary rehabilitation: one size does not fit all., Thorax, 2025.
  10. AM Walker, DR Sullivan, P Nguyen, AE Holland, N Smallwood. Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer Therapeutic Advances in Respiratory Disease 19, 2025.
  11. LM Glenn, D Jackson, C Barton, D Lan, L Fuhrmeister, K Symons, et al. Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE‐BUILD) pilot study. Respirology 30 (2), 147-157, 2025.
  12. YH Khor, V Poberezhets, RG Buhr, JD Chalmers, H Choi, VS Fan, et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine 211 (2), 174-193, 2025.
  13. AK May, AE Holland, JA Alison, K Herrmann, NS Cox. Telerehabilitation services remain increased post-COVID-19 in Australia. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 12. 2025.
  14. NS Cox, S Dal Corso, AT Burge, J Bondarenko, J Perryman, AE Holland. Remote assessment of exercise capacity in adults with chronic respiratory disease: Safety, reliability and acceptability. Chronic Respiratory Disease 22, 2025.
  15. A Pascoe, AE Holland, N Smallwood. Challenges of symptom management in interstitial lung disease: dyspnea, cough and fatigue. Expert Review of Respiratory Medicine. 2025.
  16. LM Dowman, B Vainshelboim, AE Holland. Impact of pulmonary rehabilitation on survival in people with Interstitial lung disease. Chest. 2025.
  17. EM Webb, AE Holland, AB Chang, PG Middleton, R Thomson, C Wong, et al Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry.. Pediatric Pulmonology. 2025.
  18. AT Burge, NS Cox, AE Holland, CF McDonald, JA Alison, R Wootton, et al. Telerehabilitation Compared with Center-based Pulmonary Rehabilitation for People with Chronic Respiratory Disease: Economic Analysis of a Randomized Controlled Clinical Trial. Annals of the American Thoracic Society 22 (1), 47-53.
  19. C Jenkins, AP Dickens, A Evans, P Le Cheng, F Heraud, K Hancock, et al. Patterns of Care in the Management of High-Risk COPD in Australia (2015-2019): An Observational Study for the CONQUEST Quality Improvement Program. The Lancet Regional Health-Western Pacific. 2025.
  20. Y Hamada, PG Gibson, VL Clark, H Lewthwaite, M Fricker, D Thomas, McDonald VM. Dysfunctional breathing and depression are core extrapulmonary and behavior/risk factor traits in type 2-high severe asthma. The Journal of Allergy and Clinical. Immunology: In Practice. 2025.
  21. J Fingleton, R McLachlan, J Sparks, R Beasley, A Agustí, PG Gibson…VM McDonald. Treatable trait guided asthma management: A feasibility study. Respirology. 2025.
  22. SA Hiles, H Lewthwaite, VL Clark, AE Vertigan, A Smith, VM McDonald. Social determinants of mental health in asthma: an exploratory study. Frontiers in Allergy 5, 2025.
  23. NA Negewo, NM Niessen, PJ Baines, EJ Williams, N Fibbens…PG Gibson…VM McDonald et al.,. Targeted DNase treatment of obstructive lung disease: a pilot randomised controlled trial. ERJ Open Research 11 (1). 2025.
  24. V Murphy, P Gibson, A Collison, W Karmaus, E Holliday, G Morgan, et al. Perinatal outcomes of bushfire smoke exposure in women with asthma. Journal of Allergy and Clinical Immunology 155 (2). 2025.
  25. Y Hamada, PG Gibson, ES Harvey, S Stevens, H Lewthwaite, M Fricker, VM McDonald et al. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. The Journal of Allergy and Clinical Immunology: In Practice 13 (2), 333-342. e9. 2025.
  26. MR Sarwar, VM McDonald, MJ Abramson, S Wilson, AE Holland, et al. Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study. International Journal of Clinical Pharmacy 47 (1), 157-165. 2025.
  27. Y Hamada, D Thomas, ES Harvey, S Stevens, M Fricker, H Lewthwaite, VM McDonald… PG Gibson et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. European Respiratory Journal 65 (1). 2025.
  28. Peter Gerard Gibson. My Lungs Have Feelings Too! Respirology. 2025.
  29. Elena Kum; Gordon H. Guyatt; Rayid Abdulqawi; Peter Dicpinigaitis; Lieven Dupont; Stephen K. Field; Cynthia L. French; Peter G. Gibson; Richard S. Irwin; Faye Johnston et al. The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough. European Respiratory Journal. 2025.
  30. Bronwyn K Brew; Peter G Gibson; Adam M Collison; Joerg Mattes; Gabriela Martins; Costa Gomes; Annelies Robijn; Megan E Jensen; Wilfried Karmaus; Paul Robinson et al. 1Infant respiratory outcomes following asthma management and exacerbations in pregnancy. ERJ Open Research.
  31. Peter Gerard Gibson. The good doctor. Respirology. Contributors: 2025.
  32. Pavord ID, Gibson PG. ‘Cough Reflex Hypersensitivity: A Common and Important Treatable Trait’. Journal of Allergy and Clinical Immunology: In Practice, 13 499-500 (2025).
  33. Bronwyn K. Brew, Vanessa E. Murphy, Adam M. Collison, Joerg Mattes, Wilfried Karmaus, Geoffrey Morgan, Bin Jalaludin, Graeme Zosky, Yuming Guo, Peter G. Gibson. Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations, Environmental Pollution. 2025.
  34. Elvidge E, Murphy VE, Rao M, Gibson PG, McLaughlin K, Robijn A, et al., ‘What are the broader impacts and value from a randomised controlled trial conducted in six public hospital antenatal clinics in Australia? An impact assessment using the Framework to Assess the Impact from Translational health research.’ BMJ Open, (2025).
  35. 2025 Price OJ, Papadopoulos NG, Amérigo DA, Backer V, Bougault V, Del Giacco S, et al., ‘Exercise Recommendations and Practical Considerations for Asthma Management An EAACI Position Paper’, Allergy: European Journal of Allergy and Clinical Immunology, (2025)
  36. Leong P, Clark VL, Gibson PG, McDonald VM, Bardin PG, ‘A Global Achievement: Introducing the Inducible Laryngeal Dysfunction/Vocal Cord Dysfunction Toolkit A Free Global, Peer-Reviewed Clinical Resource’, Respirology, 2025.
  37. Jenkins C, Dickens AP, Evans A, Le Cheng P, Heraud F, Hancock K, et al., ‘Patterns of care in the management of high-risk COPD in Australia (2015 2019): an observational study for the CONQUEST quality improvement program’, The Lancet Regional Health – Western Pacific, 58 (2025)
  38. Jensen ME, Harvey S, Dizon J, Holliday E, Weaver N, Barrass K, et al., ‘Asthma, gestational diabetes and adverse perinatal outcomes: a population-based obstetrics records analysis.’, The journal of allergy and clinical immunology. In practice, S2213-2198(25)00379-4 (2025)
  39. McLaughlin K, Jensen ME, Burke J, Drake J, Fredericks B, Johns A, et al., ‘”If I’m not getting oxygen, neither is my baby”: A qualitative study of Australian women’s experiences of asthma management in pregnancy’, Women and Birth, 38 (2025).
  40. Brew BK, Murphy VE, Collison AM, Mattes J, Karmaus W, Morgan G, et al., ‘Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations’, Environmental Pollution, 364 (2025).
  41. Abraham E, Barlow RO, Bhatia R, Whalen OM, Beyene T, Murphy VE, ‘Maternal exposure to particulate matter and nitrogen oxides during pregnancy and attention deficit hyperactivity disorder in offspring: a systematic review and meta-analysis’, Reviews on Environmental Health, (2025).
  42. Elvidge E, Murphy VE, Rao M, Gibson PG, McLaughlin K, Robijn A, et al., ‘What are the broader impacts and value from a randomised controlled trial conducted in six public hospital antenatal clinics in Australia? An impact assessment using the Framework to Assess the Impact from Translational health research.’, BMJ Open, 15 e082795 (2025).
  43. Jensen ME, Harvey S, Dizon J, Holliday E, Weaver N, Barrass K, et al., ‘Asthma, gestational diabetes and adverse perinatal outcomes: a population-based obstetrics records analysis.’, The journal of allergy and clinical immunology. In practice, S2213-2198(25)00379-4 (2025).
  44. LE Ruane, J Koh, M Baxter, P Finlay, K Low, R Hillman et al., Vocal cord dysfunction/inducible laryngeal obstruction induced by hyperventilation in healthy individuals, people with asthma, and following coronavirus infection. Journal of Asthma, 2025.
  45. Eathorne, A., et al. (2025). “Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand.” Respirology 30(3): 206-216.
  46. Kung, S., et al. (2025). “Efficacy of Noninvasive Ventilation With Expiratory Washout in Stable COPD Patients.” Respiratory Care 70(1): 29-37.
  47. Meulmeester, F. L., et al. (2025). “Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.” The Lancet Respiratory Medicine.
  48. Couillard, S., et al. (2025). “Choosing the Right Biologic for the Right Patient With Severe Asthma.” Chest 167(2): 330-342.
  49. Dijk, L., Y. H. Gerritsma, T. Van der Molen, H. Kerstjens, J. Kocks, I. Pavord and R. J. Meijer (2025). “Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.” International Journal of COPD 20: 1189-1201.
  50. Fokkens, W. J., V. Backer, V. J. Lund, P. J. Barnes, M. Bernal-Sprekelsen, L. Bjermer, E. de Corso, D. M. Conti, M. E. Cornet, Z. Diamant, R. Djukanovic, M. Gaga, P. Gevaert, J. K. Han, C. Hopkins, G. Joos, B. N. Landis, S. Lau, S. E. Lee, J. Mullol, A. T. Peters, G. K. Scadding, S. Schneider, B. Senior, I. D. Pavord, S. Quirce, D. Ryan, M. E. Wechsler and P. W. Hellings (2025). “Pocket guide: biologics in upper and lower airways in adults.” Rhinology 63(2): 242-244.
  51. Halpin, D. M. G., J. Balmes, M. K. Han, A. Papi, F. J. Martinez, M. M. de Oca, O. B. Ozoh, S. Salvi, D. D. Sin, J. Zheng, A. Agusti, C. Vogelmeier, A. Anzueto, J. Bourbeau, B. R. Celli, G. J. Criner, I. Pavord, N. Roche, D. Singh, R. Stockley, T. Troosters and J. A. Wedzicha (2025). “Climate Change and Chronic Obstructive Pulmonary Disease A GOLD Science Committee Review.” American Journal of Respiratory and Critical Care Medicine 211(5): 700-708.
  52. Howell, I., A. Howell and I. Pavord (2025). “Navigating uncertainty: asthma biologics during pregnancy.” The Lancet Respiratory Medicine 13(1): 10-11.
  53. Jesenak, M., A. Bobcakova, R. Djukanovic, M. Gaga, N. A. Hanania, L. G. Heaney, I. Pavord, S. Quirce, D. Ryan, W. Fokkens, D. Conti, P. W. Hellings, G. Scadding, E. Van Staeyen, L. H. Bjermer and Z. Diamant (2025). “Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care.” Chest 167(4): 956-974.
  54. Lavoie, G., I. Howell, J. Melhorn, C. Borg, L. Bermejo-Sanchez, J. Seymour, M. F. Jabeen, A. Fries, G. Hynes, I. D. Pavord, N. Petousi and T. S. C. Hinks (2025). “Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.” Thorax 80(2): 113-116.
  55. Meulmeester, F. L., S. Mailhot-Larouche, C. Celis-Preciado, S. Lemaire-Paquette, S. Ramakrishnan, M. E. Wechsler, G. Brusselle, J. Corren, J. Hardy, S. E. Diver, C. E. Brightling, M. Castro, N. A. Hanania, D. J. Jackson, N. Martin, A. Laugerud, E. Santoro, C. Compton, M. E. Hardin, C. T. J. Holweg, A. Subhashini, T. S. C. Hinks, R. W. Beasley, J. K. Sont, E. W. Steyerberg, I. D. Pavord and S. Couillard (2025). “Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.” The Lancet Respiratory Medicine.
  56. Pavord, I. D., C. E. Brightling, S. Korn, N. L. Martin, S. S. Ponnarambil, N. A. Molfino, J. R. Parnes and C. S. Ambrose (2025). “Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.” Pulmonary Therapy.
  57. Pavord, I. D., K. F. Rabe, E. Israel, S. J. Szefler, G. Brusselle, N. Pandit-Abid, A. Altincatal, Z. Chen, N. Amin, A. H. Khan, D. J. Lederer, Y. Zhang, P. J. Rowe, Y. Deniz, A. Radwan, J. A. Jacob-Nara and W. W. Busse (2025). “Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.” Journal of Allergy and Clinical Immunology: In Practice 13(1): 132-142.
  58. Pavord, I. D., M. E. Wechsler, W. W. Busse, C. Domingo, C. Xia, R. Gall, N. Pandit-Abid, J. A. Jacob-Nara, A. Radwan, P. J. Rowe and Y. Deniz (2025). “Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions.” Journal of Allergy and Clinical Immunology: Global 4(3).
  59. Perikleous, A., S. J. Bowen, C. Griffiths, I. Pavord, M. Rosenthal, L. Fleming and A. Bush (2025). “Blood Eosinophil Count: Lack of Stability and Association with Wheeze Attacks in Preschool Children.” American Journal of Respiratory and Critical Care Medicine 211(2): 263-265.
  60. Ramakrishnan, S., R. E. K. Russell, H. R. Mahmood, K. Krassowska, J. Melhorn, C. Mwasuku, I. D. Pavord, L. Bermejo-Sanchez, I. Howell, M. Mahdi, S. Peterson, T. Bengtsson and M. Bafadhel (2025). “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.” The Lancet Respiratory Medicine 13(1): 59-68.
  61. Sciurba, F. C., G. J. Criner, S. A. Christenson, F. J. Martinez, A. Papi, N. Roche, J. Bourbeau, S. Korn, M. Bafadhel, M. K. Han, S. Kolterer, K. Miller, D. Mouneimne, J. Fletcher, B. Mayer, J. Min and I. D. Pavord (2025). “Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.” The New England journal of medicine 392(17): 1710-1720.
  62. Singh, D., C. E. Brightling, K. F. Rabe, M. K. Han, S. A. Christenson, M. B. Drummond, A. Papi, I. D. Pavord, N. A. Molfino, G. Almqvist, A. Kotalik, Å. Hellqvist, M. Gołąbek, N. S. Sindhwani and S. S. Ponnarambil (2025). “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.” The Lancet Respiratory Medicine 13(1): 47-58.
  63. Singh, D., R. Stockley, A. Anzueto, A. Agusti, J. Bourbeau, B. R. Celli, G. J. Criner, M. K. Han, F. J. Martinez, M. M. de Oca, O. B. Ozoh, A. Papi, I. Pavord, N. Roche, S. Salvi, D. D. Sin, T. Troosters, J. Wedzicha, J. Zheng, C. Volgelmeier and D. Halpin (2025). “GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.” European Respiratory Journal 65(2).
  64. Wechsler, M. E., I. D. Pavord, A. Papi, K. R. Chapman, A. Altincatal, N. Pandit-Abid, J. A. Jacob-Nara, P. J. Rowe, Y. Deniz, E. Laws, B. Akinlade, N. Amin, H. W. Staudinger, D. J. Lederer and M. Hardin (2025). Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide. CHEST Pulmonary.
  65. Hayes D, Jennerich AL, Coleman RD, Abston E, Adamson GT, Berger JT, et al., ‘Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy: An Official American Thoracic Society Clinical Practice Guideline.’, Am J Respir Crit Care Med, 211 157-173 (2025)
  66. Ekström M, Li PZ, Lewthwaite H, Bourbeau J, Tan WC, Jensen D, Canadian Cohort Obstructive Lung Disease Collaborative Research Group, ‘Phenotyping Exertional Breathlessness Using Cardiopulmonary Cycle Exercise Testing in People With Chronic Airflow Limitation.’, Chest, (2025)
  67. Ekström M, Lewthwaite H, Li PZ, Bourbeau J, Tan WC, Jensen D, CanCOLD Collaborative Research Group, ‘Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing.’, Chest, 167 697-711 (2025)

 

2024

  1. Agusti A, Gibson PG, Heaney LG, Thomas M. Change is in the air: key questions on the ‘Treatable Traits’ model for chronic airway diseases in primary care. NPJ Prim Care Respir Med. 2024;34(1):21.
  2. Anderson WC, 3rd, Baptist AP, Eakin MN, Federman A, Murphy VE. Adherence Challenges and Strategies in Specific Groups With Asthma: Adolescents, Pregnancy, and Older Adults. J Allergy Clin Immunol Pract. 2024;12(12):3216-22.
  3. Bacharier LB, Pavord ID, Maspero JF, Jackson DJ, Fiocchi AG, Mao X, et al. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma. J Allergy Clin Immunol. 2024;154(1):101-10.
  4. Bardin P. VCD/ILO: Seeing and believing. Respirology. 2024;29(7):633-4.
  5. Bardin P. The raw stuff we cannot do without. Respirology. 2024;29(2):185-6.
  6. Bardin P. Cough suppression as a radical but effective therapeutic strategy. Respirology. 2024;29(12):1103-4.
  7. Barry T, Holliday M, Sparks J, Biggs R, Colman A, Lamb R, et al. START CARE: a protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children. ERJ Open Res. 2024;10(2).
  8. Beasley R. Air pollution and global health: Need to prioritize alongside tobacco control. Respirology. 2024;29(8):731-2.
  9. Beasley R. The low hanging fruit of anti-inflammatory reliever therapy. Respirology. 2024;29(3):256-7.
  10. Beasley R, Ferreira DS, Papi A. As-needed Dual Inhaled Corticosteroid-Formoterol in Mild Asthma: Scientific Evidence. Arch Bronconeumol. 2024;60(4):197-9.
  11. Beasley R, Hughes R, Agusti A, Calverley P, Chipps B, Del Olmo R, et al. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. Am J Respir Crit Care Med. 2024;209(4):390-401.
  12. Beasley R, Noble J. Time for the lens to focus on diagnostic algorithms in asthma. EClinicalMedicine. 2024;76:102812.
  13. Beasley R, Noble J, Weatherall M. Extending Personalized Evidence-Based Medicine in Severe Asthma. J Allergy Clin Immunol Pract. 2024;12(9):2362-3.
  14.  Beasley R, Noble J, Weatherall M. The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma. Eur Respir J. 2024;63(6).
  15. Beyene T, Gibson PG, Murphy VE, Jensen ME, McDonald VM. Personal strategies to reduce the effects of landscape fire smoke on asthma-related outcomes: a protocol for systematic review and meta-analysis. BMJ Open. 2024;14(2):e069516.
  16. Bondarenko J, Dal Corso S, Dillon MP, Singh S, Miller BR, Kein C, et al. Clinically important changes and adverse events with centre-based or home-based pulmonary rehabilitation in chronic respiratory disease: A systematic review and meta-analysis. Chron Respir Dis. 2024;21:14799731241277808.
  17. Boulet LP, Abbott C, Brusselle G, Edwards D, Oppenheimer J, Pavord ID, et al. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024;12(5):1244-53.e8.
  18. Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, et al. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. J Allergy Clin Immunol Pract. 2024;12(4):809-23.
  19. Brew BK, Murphy VE, Collison AM, Mattes J, Karmaus W, Morgan G, et al. Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations. Environ Pollut. 2025;364(Pt 2):125348.
  20. Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, et al. Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study. Ann Allergy Asthma Immunol. 2024;133(3):310-7.e4.
  21. Burge AT, Cox NS, Holland AE, McDonald CF, Alison JA, Wootton R, et al. Telerehabilitation Compared to Center-based Pulmonary Rehabilitation for People with Chronic Respiratory Disease: Economic Analysis of a Randomized, Controlled Clinical Trial. Ann Am Thorac Soc. 2024.
  22. Burge AT, Gadowski AM, Jones A, Romero L, Smallwood NE, Ekström M, et al. Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review. Eur Respir Rev. 2024;33(174).
  23. Burge AT, Gadowski AM, Romero L, Vagheggini G, Spathis A, Smallwood NE, et al. The effect of graded exercise therapy on fatigue in people with serious respiratory illness: a systematic review. Eur Respir Rev. 2024;33(174).
  24. Busse WW, Pavord ID, Wechsler ME, Davila IJ, Altincatal A, de Prado Gomez L, et al. Stability of Fractional Exhaled Nitric Oxide and its Relationship with Exacerbation in Patients Aged 6 Years or Older with Uncontrolled, Moderate-to-Severe Asthma. Chest. 2024.
  25.  Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024;79(5):1134-45.
  26. Chan AHY, Leong P, Politis J, McDonald VM, Bardin P. Patient-reported outcomes: missing in asthma remission. Lancet Respir Med. 2024;12(9):665-6.
  27. Chen W, Tran TN, Sadatsafavi M, Murray RB, Boon Wong NC, Ali N, et al. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”. J Allergy Clin Immunol Pract. 2024;12(2):536-9.
  28. Child CE, Ho LA, Lachant D, Gupta N, Moss J, Jones A, et al. Unsupervised Exercise in Interstitial Lung Disease: A Delphi Study to Develop a Consensus Preparticipation Screening Tool for Lymphangioleiomyomatosis. Chest. 2024;166(5):1108-23.
  29. Chipps BE, Papi A, Beasley R, Israel E, Panettieri RA, Jr., Albers FC, et al. Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation. J Allergy Clin Immunol Pract. 2024;12(10):2847-51.
  30. Chong M, Holland AE, Burge AT, Perryman J, Cox NS. Telerehabilitation: a key player in reducing the travel emissions cost of respiratory healthcare? Eur Respir J. 2024;64(2).
  31. Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. Chest. 2024.
  32. Cox ER, Plotnikoff RC, Gibson PG, Keating SE, Acharya S, Lewthwaite H. Prevalence of Long COVID and the Impact on Diabetes Management and Physical Activity Participation in Adults With Type 2 Diabetes: An Australia-wide Cross-sectional Online Survey. Can J Diabetes. 2024.
  33. Cox NS, Barton C, Bondarenko J, Clark R, Perryman J, Holland AE. Characterizing pulmonary rehabilitation referrals from primary care. Respir Med. 2024;234:107822.
  34. Cox NS, Bondarenko J, Chong M, Marceu T, Perryman J, Holland AE. Rapid real-world implementation of pulmonary telerehabilitation: good fortune or COVID-19 luck? ERJ Open Res. 2024;10(1).
  35. Cox NS, Rawlings S, Lannin NA, Candy S, Bhatt SP, Babu AS, et al. Supporting delivery of remote pulmonary rehabilitation across different healthcare contexts: A multi-national study. Chron Respir Dis. 2024;21:14799731241290518.
  36. Dal Corso S, Holland AE, George J, Abramson MJ, Russell G, Zwar N, et al. Fidelity of a home-based pulmonary rehabilitation program in people with COPD referred from primary care. Chron Respir Dis. 2024;21:14799731241307247.
  37. De Queiroz Andrade E, Sena C, de Gouveia Belinelo P, Robinson PD, Blaxland A, Sly PD, et al. In utero smoking exposure induces changes to lung clearance index and modifies risk of wheeze in infants. Pediatr Pulmonol. 2024;59(6):1686-94.
  38. Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024;79(10):2700-16.
  39. Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. Am J Respir Crit Care Med. 2024;210(3):288-97.
  40. Doppen M, Kearns C, Hills T, Weatherall M, Beasley R. Intramuscular vaccination needle length: a call to arms. Lancet. 2024;403(10426):528-9.
  41. Dowman LM, Holland AE. Pulmonary rehabilitation in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2024;30(5):516-22.
  42.  Duszyk K, McDonald VM, Thomas D, Steel K, Gibson PG. The treatable traits of asthma in pregnancy: a clinical audit. ERJ Open Res. 2024;10(3).
  43. Eapen AA, Gupta MR, Lockey RF, Bardin PG, Baptist AP. Gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction-overlapping conditions that affect asthma. J Allergy Clin Immunol. 2024;154(6):1369-77.
  44.  Ferguson CE, Lambell KJ, Ridley EJ, Goh GS, Hodgson CL, Holland AE, et al. Muscularity of older trauma patients at intensive care unit admission, association with functional outcomes, and relationship with frailty: A retrospective observational study. Aust Crit Care. 2024;37(2):205-11.
  45. Freeman-Sanderson A, Crisp J, Hodgson CL, Holland AE, Harrold M, Chan T, et al. Prevalence, recovery, and factors associated with dysphagia in an older critically ill trauma cohort: A cross-sectional study. Aust Crit Care. 2024;37(6):957-63.
  46. Frei DR, Moore MR, Bailey M, Beasley R, Campbell D, Leslie K, et al. Associations between the intraoperative fraction of inspired intraoperative oxygen administration and days alive and out of hospital after surgery. BJA Open. 2024;9:100253.
  47. Fricker M, Harrington J, Hiles SA, Gibson PG. Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma. Allergy. 2024;79(11):3118-28.
  48. Garcia G, van Dijkman SC, Pavord I, Singh D, Oosterholt S, Fulmali S, et al. A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma. Adv Ther. 2024;41(8):3196-216.
  49. Gibson PG. The good doctor. Respirology. 2024;29(11):996-7.
  50. Gibson PG, McDonald VM. Integrating hot topics and implementation of treatable traits in asthma. Eur Respir J. 2024;64(6).
  51. Gibson PG, Urroz Guerrero PD, Poon C, Rutherford N, Brooker B, Smith A, et al. Ventilation Heterogeneity Is a Treatable Trait in Severe Asthma. J Allergy Clin Immunol Pract. 2024;12(4):929-35.e4.
  52. Gomez HM, Haw TJ, Ilic D, Robinson P, Donovan C, Croft AJ, et al. Landscape fire smoke airway exposure impairs respiratory and cardiac function and worsens experimental asthma. J Allergy Clin Immunol. 2024;154(1):209-21.e6
  53. Hamada Y, Gibson PG, Harvey ES, Stevens S, Lewthwaite H, Fricker M, et al. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2024.
  54. Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2024.
  55. Hao Q, Brooks D, Ellerton C, Goldstein R, Lee AL, Alison JA, et al. Pulmonary rehabilitation with balance training for fall reduction in chronic obstructive pulmonary disease: a randomized controlled trial. BMC Pulm Med. 2024;24(1):408.
  56. Hatter L, Holliday M, Eathorne A, Bruce P, Pavord ID, Reddel HK, et al. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. Eur Respir J. 2024;64(1).
  57. He LX, Deng K, Wang J, Zhang X, Wang L, Zhang HP, et al. Clinical Subtypes of Neutrophilic Asthma: A Cluster Analysis From Australasian Severe Asthma Network. J Allergy Clin Immunol Pract. 2024;12(3):686-98.e8.
  58. Hoffman M, Burge AT, Wong N, McDonald CF, Chambers DC, Glaspole I, et al. Exertional Desaturation During the 6-Minute Walk Test vs Daily Life in People With Fibrotic Interstitial Lung Disease. Chest. 2024;165(3):632-5.
  59. Holland A, Corso SD. The Alfred Health post-COVID-19 service, Melbourne, 2020-2022: an observational cohort study. Med J Aust. 2024;221(4):226.
  60. Holland AE. Appraisal of Clinical Practice Guideline: Telerehabilitation in Physical Therapist Practice: A Clinical Practice Guideline From the American Physical Therapy Association. J Physiother. 2024;70(4):317.
  61. Holland AE, Dowman L. Using change in 6-minute walk distance to predict survival in progressive pulmonary fibrosis: A promising measure in need of precision. Respirology. 2024;29(5):359-60.
  62.  Holland AE, Fineberg D, Marceau T, Chong M, Beaman J, Wilson L, et al. The Alfred Health post-COVID-19 service, Melbourne, 2020-2022: an observational cohort study. Med J Aust. 2024;220(2):91-6.
  63. Holland AE, Lewis A. Evidence-based management of symptoms in serious respiratory illness: what is in our toolbox? Eur Respir Rev. 2024;33(174).
  64. Holland AE, Spathis A, Marsaa K, Bausewein C, Ahmadi Z, Burge AT, et al. European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness. Eur Respir J. 2024;63(6).
  65. Holland AE, Woollett A, Goh N, Glaspole I. Respiratory teletrials-A call for equitable access to clinical trials for people with respiratory conditions. Respirology. 2024;29(8):659-61
  66. Howell I, Bratton DJ, Hynes G, Yancey SW, Heaney LG, Pavord ID, et al. Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo. ERJ Open Res. 2024;10(4).
  67. Howell I, Howell A, Pavord I. Navigating uncertainty: asthma biologics during pregnancy. Lancet Respir Med. 2024.
  68. Howell I, Howell A, Ramakrishnan S, Bafadhel M, Pavord I. How have we measured trial outcomes of asthma attack treatment? A systematic review. ERJ Open Res. 2024;10(1).
  69. Howell I, Yang F, Brown V, Cane J, Marchi E, Azim A, et al. Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma. J Allergy Clin Immunol. 2024;154(5):1146-58.
  70. Huang D, Zhang L, Liu Y, Wang J, Zhang J, Baines KJ, et al. Activated non-neuronal cholinergic system correlates with non-type 2 inflammation and exacerbations in severe asthma. Ann Allergy Asthma Immunol. 2024;133(1):64-72.e4.
  71. Jabeen MF, Sanderson ND, Tinè M, Donachie G, Barber C, Azim A, et al. Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma. Allergy. 2024;79(11):2966-80.
  72.  Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024.
  73. Jeffery J, Vertigan AE, Bone S, Gibson PG. Abnormal breathing pattern features in chronic refractory cough. ERJ Open Res. 2024;10(6).
  74. Jenkins AR, Burtin C, Camp PG, Lindenauer P, Carlin B, Alison JA, et al. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis. Thorax. 2024;79(5):438-47.
  75. Jenkins AR, Cox NS, Tappan RS, Holland AE, Rochester CL, Alison JA, et al. Summary for Clinicians: Clinical Practice Guideline on Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease. Ann Am Thorac Soc. 2024;21(4):533-7.
  76.  Jones AW, King BE, Cumella A, Hopkinson NS, Hurst JR, Holland AE. Use of infection control measures in people with chronic lung disease: mixed methods study. ERJ Open Res. 2024;10(1).
  77. Keijzers G, Donaghy M, Weatherall M, Beasley R, Ball EL, Simpson G, et al. Primary spontaneous pneumothorax: does size matter? Eur Respir J. 2024;64(1).
  78. Khaleva E, Brightling C, Eiwegger T, Altraja A, Bégin P, Blumchen K, et al. Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma. Eur Respir J. 2024.
  79. Khor YH, Poberezhets V, Buhr RG, Chalmers JD, Choi H, Fan VS, et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2024.
  80. Kimmel LA, Raper E, Harris IA, Ackerman IN, Page R, Naylor JM, et al. HIP fracture Supplemental Therapy to Enhance Recovery (HIPSTER): a protocol for a randomised controlled trial. BMJ Open. 2024;14(1):e079846.
  81. Kirton L, Kung S, Bird G, Black M, Semprini R, Eathorne A, et al. Automated oxygen titration with non-invasive ventilation in hypoxaemic adults with cardiorespiratory disease: a randomised cross-over trial. BMJ Open Respir Res. 2024;11(1).
  82. Kirton LW, Cruz RS, Navarra L, Eathorne A, Cook J, Beasley R, et al. Effect of automated titration of oxygen on time spent in a prescribed oxygen saturation range in adults in the ICU after cardiac surgery. Crit Care Resusc. 2024;26(2):64-70.
  83. Kok HC, McCallum GB, Yerkovich ST, Grimwood K, Fong SM, Nathan AM, et al. Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial. Pediatr Infect Dis J. 2024;43(9):872-9.
  84. Krings JG, Beasley R. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J Allergy Clin Immunol Pract. 2024;12(4):870-9.
  85. Kuek SL, Wong NX, Dalziel S, Hatter L, Fleming L, Bush A, et al. Dry-powder inhaler use in primary school-aged children with asthma: a systematic review. ERJ Open Res. 2024;10(6).
  86. Kum E, Guyatt GH, Abdulqawi R, Dicpinigaitis P, Dupont L, Field SK, et al. The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough. Eur Respir J. 2024.
  87. Kung S, Semprini AC, Kirton LW, Fogarin JR, Zoellner SK, Beasley R, et al. Efficacy of Noninvasive Ventilation With Expiratory Washout in Stable COPD Patients. Respir Care. 2024.
  88. Lamb R, Kerse K, Kristono H, Oldfield K, Beasley R. A snapshot of SABA co-prescribing with ICS-formoterol maintenance and reliever therapy. Respirology. 2024;29(10):922-3
  89. Lavoie G, Pavord ID. Biologics in Asthma: Role of Biomarkers. Immunol Allergy Clin North Am. 2024;44(4):709-23.
  90. Lee JYT, Tikellis G, Hoffman M, Mellerick CR, Symons K, Bondarenko J, et al. A self-management package for pulmonary fibrosis: A feasibility study. PEC Innov. 2024;5:100328.
  91.  Lee TY, Price D, Yadav CP, Roy R, Lim LHM, Wang E, et al. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma. Chest. 2024;166(1):28-38.
  92. Levy ML, Beasley R, Bostock B, Capstick TG, Crooks MG, Fleming L, et al. A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy. Br J Gen Pract. 2024;74(739):86-9.
  93. Lewthwaite H, Gibson PG, Guerrero PDU, Smith A, Clark VL, Vertigan AE, et al. Understanding Breathlessness Burden and Psychophysiological Correlates in Asthma. J Allergy Clin Immunol Pract. 2024;12(10):2754-63.e17.
  94. Loewenthal L, Busby J, McDowell R, Brown T, Burhan H, Chaudhuri R, et al. Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care. Thorax. 2024;79(5):403-11.
  95. Lommatzsch M, Buhl R, Canonica GW, Ribas CD, Nagase H, Brusselle GG, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024;12(2):96-9.
  96. Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, et al. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. Mucosal Immunol. 2024;17(4):524-36.
  97. Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, et al. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. 2024;29(2):105-35.
  98. Mackle DM, Nelson K, Beasley RW, Eathorne A, Young PJ. The Influence of Participation in an Intensive Care Trial on Health Practitioners’ Knowledge of the Results-A Self-Reported Survey. J Adv Nurs. 2024.
  99. Majellano EC, Clark VL, Vertigan A, Gibson PG, Bardin P, Leong P, et al. Living With Asthma and Vocal Cord Dysfunction/Inducible Laryngeal Obstruction: “I Just Can’t Get Air In”. J Allergy Clin Immunol Pract. 2024;12(5):1326-36.
  100. Majellano EC, Yorke J, Clark VL, Gibson PG, Smith AJ, Holmes LJ, et al. The illness burden of severe asthma contrasted to people with mild-to-moderate asthma: a qualitative study. ERJ Open Res. 2024;10(3).
  101. Maneechotesuwan K, Aggarwal B, Garcia G, Tan D, Neffen H, Javier RJM, et al. Exploring Clinical Remission in Moderate Asthma – Perspectives from Asia, the Middle East, and South America. Pulm Ther. 2024;10(3):279-95.
  102. Marchant JM, Chang AB, Kennedy E, King D, Perret JL, Schultz A, et al. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia. Med J Aust. 2024;220(1):35-45.
  103. Martins Costa Gomes G, Da Silva Sena CR, Murphy VE, Hansbro PM, Starkey MR, Gibson PG, et al. Cord blood granulocyte levels are associated with severe bronchiolitis in the first year of life. Clin Transl Immunology. 2024;13(9):e70004.
  104. May AK, Holland AE, Alison JA, Herrmann K, Cox NS. Telerehabilitation Services Remain Increased Post-COVID-19 in Australia. Chronic Obstr Pulm Dis. 2024.
  105. McDonald CF, Bardin PG, MacDonald M. Asthma-COPD overlap and asthma progressing to COPD: A complementary perspective. Respirology. 2024;29(9):759-60.
  106. McDonald VM. Let’s talk about obesity in respiratory disease. Respirology. 2024;29(5):363-5.
  107. McDonald VM, Gibson PG. Treatable traits-Where we are, where we are headed. Respirology. 2024;29(7):539-41.
  108.  McDonald VM, Hamada Y, Agusti A, Gibson PG. Treatable Traits in Asthma: The Importance of Extrapulmonary Traits-GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety. J Allergy Clin Immunol Pract. 2024;12(4):824-37.
  109. McDonald VM, Holland AE. Treatable traits models of care. Respirology. 2024;29(1):24-35.
  110. Mellerick CR, Burge AT, Hill CJ, Cox NS, Bondarenko J, Holland AE. Impact of Test Instructions on 6-min Walk Distance in Adults With Chronic Respiratory Disease: A Randomized Controlled Trial. J Cardiopulm Rehabil Prev. 2024;44(1):49-54.
  111. Murphy VE, Whalen OM, Williams EJ, Gibson PG, Campbell LE, Karayanidis F, et al. Autism likelihood in infants born to mothers with asthma is associated with blood inflammatory gene biomarkers in pregnancy. Brain Behav Immun Health. 2024;40:100845.
  112. Newman ANL, Beauchamp MK, Ellerton C, Goldstein R, Alison JA, Dechman G, et al. Reflections on the challenges of conducting an international multicentre randomized controlled trial of balance training in addition to pulmonary rehabilitation and its impact on fall incidence in people with COPD. Trials. 2024;25(1):487.
  113. Nguyen KT, Brooks D, Macedo LG, Ellerton C, Goldstein R, Alison JA, et al. Balance measures for fall risk screening in community-dwelling older adults with COPD: A longitudinal analysis. Respir Med. 2024;230:107681.
  114. Noble J, Hatter L, Eathorne A, Hills T, Bean O, Bruce P, et al. Patterns of asthma medication use and hospital discharges in New Zealand. J Allergy Clin Immunol Glob. 2024;3(3):100258.
  115.  O’Driscoll BR, Kirton L, Weatherall M, Bakerly ND, Turkington P, Cook J, et al. Effect of a lower target oxygen saturation range on the risk of hypoxaemia and elevated NEWS2 scores at a university hospital: a retrospective study. BMJ Open Respir Res. 2024;11(1).
  116. Oliveira JM, Clark VL, Furlanetto KC, Gibson PG, McDonald VM. Core Function in Adults With Severe Asthma and Its Relationship With Breathing Symptoms. J Allergy Clin Immunol Pract. 2024;12(5):1254-62.e1.
  117. Oliveira MR, Hoffman M, Jones AW, Holland AE, Borghi-Silva A. Effect of Pulmonary Rehabilitation on Exercise Capacity, Dyspnea, Fatigue, and Peripheral Muscle Strength in Patients With Post-COVID-19 Syndrome: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2024;105(8):1559-70.
  118. Oppenheimer J, Kerstjens HA, Boulet LP, Hanania NA, Kerwin E, Moore A, et al. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024;12(9):2372-80.e5.
  119. Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, et al. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma. Respir Med. 2024;224:107535.
  120.  Papi A, Chipps BE, Beasley R, Panettieri RA, Jr., Israel E, Cooper M, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma: a plain language summary of the MANDALA study. Ther Adv Respir Dis. 2024;18:17534666241232264.
  121. Papi A, Faner R, Pavord I, Baraldi F, McDonald VM, Thomas M, et al. From treatable traits to GETomics in airway disease: moving towards clinical practice. Eur Respir Rev. 2024;33(171).
  122.  Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price RG, et al. Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study. Ann Med. 2024;56(1):2417184.
  123. Pavord ID. Remission in the World of Severe Asthma. Am J Respir Crit Care Med. 2024;210(7):855-7.
  124. Pavord ID. The Rebirth of Lebrikizumab for Airway Disease. J Allergy Clin Immunol Pract. 2024;12(5):1225-7.
  125. Pavord ID. New thinking and a new direction in bronchiectasis. Lancet Respir Med. 2024;12(11):844-5.
  126. Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, et al. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2024;12(7):1763-72.
  127. Pavord ID, De Prado Gómez L, Brusselle G, Jackson DJ, Brightling CE, Papi A, et al. Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma. Am J Respir Crit Care Med. 2024;209(8):1031-3.
  128. Pavord ID, Rabe KF, Israel E, Szefler SJ, Brusselle G, Pandit-Abid N, et al. Dupilumab Induces Long-term On-Treatment Clinical Remission in Patients With Type 2 Asthma. J Allergy Clin Immunol Pract. 2024.
  129. Pelaia C, Melhorn J, Hinks TS, Couillard S, Vatrella A, Pelaia G, et al. Type 2 severe asthma: pathophysiology and treatment with biologics. Expert Rev Respir Med. 2024;18(7):485-98.
  130. Perez-de-Llano L, Scelo G, Canonica GW, Chen W, Henley W, Larenas-Linnemann D, et al. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma. Ann Allergy Asthma Immunol. 2024;132(5):610-22.e7.
  131. Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, et al. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024;210(7):869-80.
  132. Perikleous A, Bowen SJ, Griffiths C, Pavord I, Rosenthal M, Fleming L, et al. Blood Eosinophil Count: Lack of Stability and Association with Wheeze Attacks in Preschool Children. Am J Respir Crit Care Med. 2024.
  133.  Petousi N, Pavord ID, Kent BD. Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease. Thorax. 2024;79(4):291-2.
  134. Pizzichini E, Brusselle G, Edwards D, Gibson PG, Kerstjens HA, Moore A, et al. Run-in periods and treatment outcomes in asthma trials: A narrative review. Contemp Clin Trials Commun. 2024;42:101382.
  135. Politis J, Bardin PG, Leong P. Contemporary Concise Review 2023: Asthma. Respirology. 2024;29(8):674-84.
  136. Politis J, Chung LP, Igwe E, Bardin P, Gibson PG. Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry. Intern Med J. 2024;54(7):1136-45.
  137. Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, et al. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024;15:1361891.
  138. Poulsen M, Holland AE, Button B, Jones AW. Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study. Pediatr Pulmonol. 2024;59(5):1217-26.
  139. Ramakrishnan S, Montgomery B, Pavord ID. Blood eosinophils and lung function loss: from passive prediction to active prevention? Eur Respir J. 2024;63(5).
  140. Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2024.
  141. Raper E, Kimmel LA, Burge AT, Harris IA, Ackerman IN, Page RS, et al. Implementation of supplemental physiotherapy following hip fracture surgery: a protocol for the process evaluation of a randomised controlled trial. Trials. 2024;25(1):344.
  142. Raymond MJ, Christie LJ, Kramer S, Malaguti C, Mok Z, Gardner B, et al. Delivery of Allied Health Interventions Using Telehealth Modalities: A Rapid Systematic Review of Randomized Controlled Trials. Healthcare (Basel). 2024;12(12).
  143. Robijn AL, Harvey SM, Jensen ME, Atkins S, Quek KJD, Wang G, et al. Adverse neonatal outcomes in pregnant women with asthma: An updated systematic review and meta-analysis. Int J Gynaecol Obstet. 2024;166(2):596-606.
  144. Ruane LE, Denton E, Bardin PG, Leong P. Dysfunctional breathing or breathing pattern disorder: New perspectives on a common but clandestine cause of breathlessness. Respirology. 2024;29(10):863-6.
  145. Rupani H, Busse WW, Howarth PH, Bardin PG, Adcock IM, Konno S, et al. Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma. Allergy. 2024;79(10):2589-604.
  146.  Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, et al. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma. Eur Respir J. 2024;63(4).
  147. Sarwar MR, McDonald VM, Abramson MJ, Wilson S, Holland AE, Bonevski B, et al. Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study. Int J Clin Pharm. 2024.
  148. Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024;132(1):42-53.
  149. Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, et al. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024;12(9):2347-61.
  150. Sena C, Morten M, Collison AM, Shaar A, Andrade EQ, Meredith J, et al. Bronchiolitis hospital admission in infancy is associated with later preschool ventilation inhomogeneity. Pediatr Pulmonol. 2024;59(3):632-41.
  151. Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2024.
  152. Singh D, Stockley R, Anzueto A, Agusti A, Bourbeau J, Celli BR, et al. GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD. Eur Respir J. 2024.
  153. Smallwood NE, Pascoe A, Wijsenbeek M, Russell AM, Holland AE, Romero L, et al. Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(174).
  154. Smolinska S, Popescu FD, Izquierdo E, Antolín-Amérigo D, Price OJ, Alvarez-Perea A, et al. Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper. Allergy. 2024;79(4):777-92.
  155. Spathis A, Reilly CC, Bausewein C, Reinke LF, Romero L, Smallwood NE, et al. Multicomponent services for symptoms in serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(174).
  156. Thomas D, McDonald VM, Gibson PG. Realignment of clinical research after the COVID-19 era. Lancet Respir Med. 2024;12(6):428-30.
  157. Thomas D, McDonald VM, Stevens S, Baraket M, Hodge S, James A, et al. Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. 2024;166(2):262-70.
  158. Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024;79(2):384-92.
  159. Thottiyil Sultanmuhammed Abdul Khadar B, Sim J, McDonald VM, McDonagh J, Clapham M, Mitchell BG. Air Purifiers and Acute Respiratory Infections in Residential Aged Care: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(11):e2443769.
  160. Tikellis G, Corte T, Glaspole IN, Goh NSL, Khor YH, Wrobel J, et al. Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease. Chron Respir Dis. 2024;21:14799731231226236.
  161. Urroz Guerrero PD, Gibson PG, Lewthwaite H, Majellano E, Hiles SA, McDonald VM. Perceptions of sedentary behaviour in people with severe asthma: a qualitative study. BMC Public Health. 2024;24(1):3011.
  162. Urroz Guerrero PD, Lewthwaite H, Gibson PG, Clark VL, Cordova-Rivera L, McDonald VM. Physical capacity and inactivity in obstructive airway diseases: a “can do, do do” analysis. ERJ Open Res. 2024;10(4).
  163. Valkenborghs SR, Wood LG, Callister R, Upham JW, Grainge CL, Anderson S, et al. Effects of Moderate- Versus Vigorous-Intensity Exercise Training on Asthma Outcomes in Adults. J Allergy Clin Immunol Pract. 2024;12(10):2744-53.e8.
  164. van Dijkman SC, Yorgancıoğlu A, Pavord I, Brusselle G, Pitrez PM, Oosterholt S, et al. Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials. Adv Ther. 2024;41(3):1201-25.
  165. Webb EM, Holland AE, Chang AB, Burr L, Holmes-Liew CL, King PT, et al. Current physiotherapy practice for adults with bronchiectasis: Data from the Australian bronchiectasis registry. Respir Med. 2024;233:107777.
  166. Webb EM, Holland AE, Chang AB, Middleton PG, Thomson R, Wong C, et al. Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry. Pediatr Pulmonol. 2024.
  167. Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. Eur Respir J. 2024;64(6).
  168. Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, et al. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2024;209(3):262-72.
  169. Whalen OM, Campbell LE, Lane AE, Karayanidis F, Mallise CA, Woolard AJ, et al. Effect of fractional exhaled nitric oxide (F(ENO))-based asthma management during pregnancy versus usual care on infant development, temperament, sensory function and autism signs. Eur J Pediatr. 2024;183(8):3199-210.
  170. Xiao W, Chen YL, Du LY, Wu J, Wang Z, Mao B, et al. Bacterial interactome disturbance in chronic obstructive pulmonary disease clinical stability and exacerbations. Respir Res. 2024;25(1):173.

2023

  1. McLaughlin K, Jensen M, Foureur M, Murphy VE. Are pregnant women with asthma receiving guideline-recommended antenatal asthma management? A survey of pregnant women receiving usual care in Australia. Women Birth. Mar 2023.Negewo NA, Gibson PG, Simpson JL, McDonald VM, Baines KJ. Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes. Int J Chron Obsruct Pulmon Dis. Mar 2023.
  2. Beasley R, Chang AB. Is tezepelumab the ubiquitous biologic for severe asthma? Lancet Respir Med. Jan 2023
  3. Beasley R, Kankaanranta H. Inhaled Corticosteroids in Asthma: When Less Is More. J Allergy Clin Immunol Pract. Feb 2023.
  4. Beasley R, Bruce P, Hatter L. ICS/formoterol maintenance and reliever therapy: how far beyond asthma? Thorax. May 2023.
  5. Rogliani P, Laitano R, Ora J, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. Eur Respir Rev. Mar 2023.
  6. Rogliani P, Laitano R, Ora J, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. Eur Respir Rev. Mar 2023.
  7. Lee TY, Sadatsafavi M, Yadav CP, Price DB, Beasley R, Janson C, Koh MS, Roy R, Chen W. Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling study. BMJ Open. Mar 2023.
  8. Chipps BE, Israel E, Beasley R, Panettieri RA Jr, Albers FC, Rees R, Dunsire L, Danilewicz A, Johnsson E, Cappelletti C, Papi A. Albuterol-budesonide pressurized metered dose inhaler in patients with mild-to-moderate asthma: results of the DENALI double-blind randomized controlled trial. Chest. Mar 2023.
  9.  Beyene T, Zosky GR, Gibson PG, McDonald VM, Holliday EG, Horvat JC, Vertigan AE, Van Buskirk J, Morgan GG, Jegasothy E, Hanigan I, Murphy VE, Jensen ME. The impact of the 2019/2020 Australian landscape fires on infant feeding and contaminants in breast milk in women with asthma. Int Breastfeed Journal. Feb 2023.
  10. Upham JW. Can Allergen Immunotherapy Improve Antiviral Immunity in Patients with Allergic Asthma? Am J Respir Crit Care Med. Feb 2023.
  11. Zanaboni P, Dinesen B, Hoaas H, Wootton R, Burge AT, Philp R, Oliveira CC, Bondarenko J, Tranborg Jensen T, Miller BR, Holland AE. Long-term Telerehabilitation or Unsupervised Training at Home for Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Am J Respir Crit Care Med. Apr 2023.
  12. Bondarenko J, Holland AE. Clinimetrics: The Breathing Pattern Assessment Tool. J Physiotherapy. Apr 2023.
  13. Agusti A, Ambrosino N, Blackstock F, Bourbeau J, Casaburi R, Celli B, Crouch R, Negro RD, Dreher M, Garvey C, Gerardi D, Goldstein R, Hanania N, Holland AE, Kaur A, Lareau S, Lindenauer PK, Mannino D, Make B, Maltais F, Marciniuk JD, Meek P, Morgan M, Pepin JL, Reardon JZ, Rochester C, Singh S, Spruit MA, Steiner MC, Troosters T, Vitacca M, Clini E, Jardim J, Nici L, Raskin J, ZuWallack R. COPD: Providing the right treatment for the right patient at the right time. Respir Med. Feb 2023.
  14. Chang AB, Bell SC, Byrnes CA, Dawkins P, Holland AE, Kennedy E, King PT, Laird P, Mooney S, Morgan L, Parsons M, Poot B, Toombs M, Torzillo PJ, Grimwood K. Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand. Respirology. Apr 2023.
  15. Cox NS, Holland AE, Jones AW, McDonald CF, O’Halloran P, Mahal A, Hepworth G, Lannin NA. Implementation of offering choice of pulmonary rehabilitation location to people with COPD: a protocol for the process evaluation of a cluster randomised controlled trial. Trials. Mar 2023.
  16. Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunology. Feb 2023.
  17. Pavord ID, Tran TN, Jones RC, Nuevo J, van den Berge M, Brusselle GG, Menzies-Gow AN, Skinner D, Carter V, Kocks JWH, Price DB. Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study. J Allergy Clin Immunol Pract. Feb 2023.
  18. Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. Apr 2023.
  19. Eastwood MC, Busby J, Jackson DJ, Pavord ID, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan D, Mansur AH, Fowler SJ, Howarth P, Lordan J, Menzies-Gow A, Harrison T, Robinson DS, Holweg CTJ, Matthews JG, Heaney LG; Refractory Asthma Stratification Programme (UK) Investigators. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex. J Allergy Clin Immunol Pract. Apr 2023.
  20. Lommatzsch M, Brusselle GG, Levy ML, Canonica GW, Pavord ID, Schatz M, Virchow JC. A2BCD: a concise guide for asthma management. Lancet Respir Med. Jan 2023.
  21. Gern JE, Pavord ID. Challenges and Opportunities in Asthma Prevention and Treatment. J Allergy Clin Immunol Pract. Mar 2023.
  22. Rabe KF, Pavord ID, Busse WW, Chupp GL, Izuhara K, Altincatal A, Gall R, Pandit-Abid N, Deniz Y, Rowe PJ, Jacob-Nara JA, Radwan A. Dupilumab Improves Long-term Outcomes in Patients With Uncontrolled, Moderate-to-Severe GINA-Based Type 2 Asthma, Irrespective of Allergic Status. Allergy. Apr 2023.
  23. Siu H, Polkinghorne K, Finlay P, Yong T, Bardin PG, King PT. Effect of COVID-19 lockdown on body weight in chronic obstructive pulmonary disease. Intern Med J. Jan 2023.
  24. Koh J, Phyland D, Ruane L, Avram A, Leahy E, Lau KK, MacDonald M, Leong P, Baxter M, Bardin PG. Lessons from a failed randomized controlled trial of speech pathology intervention in vocal cord dysfunction. Respirology. Apr 2023.
  25.  Majellano EC, Bell RL, Flynn AW, Mckenzie A, Sivamalai S, Goldman M, Vaughan L, Gibson PG. Identifying the asthma research priorities of people with asthma, their carers and other stakeholders. Respirology. Mar 2023.
  26. Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, Peters M, Christoff GC, Sadatsafavi M, Torres-Duque CA, Altraja A, Lehtimäki L, Papadopoulos NG, Salvi S, Costello RW, Cushen B, Heffler E, Iwanaga T, Al-Ahmad M, Larenas-Linnemann D, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Perez-de-Llano L, Perng Steve DW, Mahboub B, Wang E, Goh C, Lyu J, Newell A, Alacqua M, Belevskiy AS, Bhutani M, Bjermer L, Bjornsdottir U, Bourdin A, Bulow AV, Busby J, Canonica GW, Cosio BG, Dorscheid DR, Muñoz-Esquerre M, FitzGerald JM, Gil EG, Gibson PG, Heaney LG, Hew M, Hilberg O, Hoyte F, Jackson DJ, Koh MS, Ko HB, Lee JH, Lehmann S, Chaves Loureiro C, Lúðvíksdóttir D, Menzies-Gow AN, Mitchell P, Papaioannou AI, Popov TA, Porsbjerg CM, Salameh L, Sirena C, Taillé C, Taube C, Tohda Y, Wechsler ME, Price DB. Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. Mar 2023.
  27. Beasley R, Hatter L. Over-the-counter Dispensing: Widening Access to Inhaled Corticosteroid/Formoterol Reliever Therapy. Am J Respir Crit Care Med. Feb 2023.
  28. Beasley R, Bruce P, Houghton C, Hatter L. The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review. J Allergy Clin Immunol Pract. Mar 2023.
  29. Joshi E, Gibson PG, McDonald VM, Murphy VE, ‘Treatable traits in asthma during pregnancy: a call for a shift towards a precision-based management approach’, European Respiratory Review, 32 230105-230105 (2023)
  30. Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, et al. ‘Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry.’. Ann Allergy Asthma Immunol, (2023)
  31. Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.’, Allergy, (2023)     
  32. Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, et al., ‘Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.’, Allergy, 78 1934-1948 (2023)                          
  33. He LX, Deng K, Wang J, Zhang X, Wang L, Zhang HP, et al., ‘Clinical Subtypes of Neutrophilic Asthma: A Cluster Analysis From Australasian Severe Asthma Network’, Journal of Allergy and Clinical Immunology: In Practice, (2023) 
  34. McDonald VM, Archbold G, Beyene T, Brew BK, Franklin P, Gibson PG, et al.,’Asthma and landscape fire smoke: A Thoracic Society of Australia and New Zealand position statement’, Respirology, 28 1023-1035 (2023)
  35. Ali H, Brooks C, Tzeng Y-C, Crane J, Beasley R, Gibson P, et al., Heart rate variability as a marker of autonomic nervous system activity in young people with eosinophilic and non-eosinophilic asthma.’, J Asthma, 60 534-542 (2023)                          
  36. Gibson PG, ‘Wellness safety and burnout’ Respirology. 28 958-959 (2023)
  37. Gibson PG, ‘Breathlessness’, Respirology, 28 187-188 (2023)
  38. Urroz Guerrero PD, Gibson PG, ‘A Real-World Analysis to Create Real-World Change: The Need for an Individualized Approach to Improving Physical Activity in Asthma’, The Journal of Allergy and Clinical Immunology: In Practice, 11 2801-2802 (2023)            
  39. Leong P, Gibson PG, Vertigan AE, Hew M, McDonald VM, Bardin PG, ‘Vocal cord dysfunction/inducible laryngeal obstruction-2022 Melbourne Roundtable Report’, Respirology, 28 615-626 (2023)                        
  40. Murphy VE, Gibson PG, Schatz M, ‘Managing Asthma During Pregnancy and the Postpartum Period.’, J Allergy Clin Immunol Pract, (2023)             
  41. Song W-J, Dupont L, Birring SS, Chung KF, Dabrowska M, Dicpinigaitis P, et al., ‘Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study’, ERJ Open Research, 9 00618-2023 (2023)     
  42. Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, et al., ‘Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry.’, J Allergy Clin Immunol Pract, 11 2732-2747 (2023) 
  43. Woolard A, Benders T, Campbell LE, Whalen OM, Mallise C, Karayanidis F, et al., ‘The relationship between pitch contours in infant-directed speech and early signs of autism in infancy.’, Infant Behav Dev, 72 101860 (2023)
  44. Jenkins CR, Bardin PG, Blakey J, Hancock KL, Gibson P, McDonald VM, ‘Sleepwalking towards more harm from asthma.’, Med J Aust, 219 49-52 (2023)
  45. Leong P, Vertigan AE, Hew M, Baxter M, Phyland D, Hull JH, et al., ‘Diagnosis of vocal cord dysfunction/inducible laryngeal obstruction: An International Delphi Consensus Study.’, The Journal of allergy and clinical immunology, 152 899-906 (2023) 
  46. Lewthwaite H, Byrne A, Brew B, Gibson PG, ‘Treatable traits for long COVID.’, Respirology, 28 1005-1022 (2023) 
  47. Negewo NA, Gibson PG, Simpson JL, McDonald VM, Baines KJ, ‘Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes’, International Journal of Chronic Obstructive Pulmonary Disease, Volume 18 273-287
  48. Ramsahai JM, Simpson JL, Cook A, Gibson PG, McDonald V, Grainge C, et al., ‘Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma.’, Thorax, 78 868-874 (2023) 
  49. Vertigan AE, Harvey ES, Beyene T, Van Buskirk J, Holliday EG, Bone SL, et al., ‘Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal Hypersensitivity.’, The journal of allergy and clinical immunology. In practice, 11 3107-3115.e2 (2023)
  50. Urroz Guerrero PD, Oliveira JM, Lewthwaite H, Gibson PG, McDonald VM, ‘Key Considerations When Addressing Physical Inactivity and Sedentary Behaviour in People with Asthma’, Journal of Clinical Medicine, 12 5998-5998 (2023)
  51. Zhang Q, Wu WW, Li L, McDonald VM, Chen YC, Wang G, Gibson PG, ‘Workup of difficult-to-treat asthma: implications from treatable traits.’, Precision clinical medicine, 6 pbad003 (2023)            
  52. Gibson PG, McDonald VM, Thomas D, ‘Treatable traits, combination inhaler therapy and the future of asthma management’, Respirology, 28 828-840 (2023)                                    
  53. Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, et al., ‘Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.’, J Allergy Clin Immunol Pract, 11 885-895.e13 (2023) 
  54. Lai K, Satia I, Song W-J, Wang G, Niimi A, Pattemore P, et al., ‘Cough and cough hypersensitivity as treatable traits of asthma’, lancet respiratory medicine, 11 650-662 (2023)
  55. Khadar BTSA, Sim J, McDonagh J, McDonald VM, Mitchell BG, ‘Air purifiers for reducing the incidence of acute respiratory infections in australian residential aged care facilities: A study protocol for a randomised control trial’, Infection Disease & Health, 28 239-245 (2023)
  56. Khor YH, Cottin V, Holland AE, Inoue Y, McDonald VM, Oldham J, et al., ‘Treatable traits: a comprehensive precision medicine approach in interstitial lung disease’, European Respiratory Journal, 62 (2023)                                    
  57. Wang J, Zhang X, Zhang L, Liu Y, Wang G, Zhang HP, et al., ‘Age-Related Clinical Characteristics, Inflammatory Features, Phenotypes, and Treatment Response in Asthma.’, J Allergy Clin Immunol Pract, 11 210-219.e3 (2023)
  58. Rees M, Collins CE, Majellano E, McDonald V, ‘Healthcare Professionals Perspectives of Nonsurgical Care of Older Inpatients with Class II or III Obesity and Comorbidities: A Qualitative Study’, Journal of Multidisciplinary Healthcare, Volume 16 3339-3355
  59. Wark P, McDonald VM, Smith S, ‘Nebulised hypertonic saline for cystic fibrosis.’, Cochrane Database Syst Rev, 6 CD001506 (2023) [C1]
  60. McLaughlin K, Jensen M, Foureur M, Murphy VE, ‘Are pregnant women with asthma receiving guideline-recommended antenatal asthma management? A survey of pregnant women receiving usual care in Australia’, Women and Birth, 36 108-116 (2023)             
  61. Brew BK, Gibberd A, Marks GB, Murphy VE, Jorm L, Chambers GM, et al., ‘Maternal asthma in Australian indigenous women and perinatal outcomes: A whole population-linked study.’, Int J Gynaecol Obstet, 160 653-660 (2023) 
  62. Murphy VE, Jensen ME, ‘Longitudinal Changes in Upper and Lower Airway Function in Pregnancy’, Immunology and Allergy Clinics of North America, 43 17-26 (2023)            
  63. Grace T, Fisher J, Wang C, Valkenborghs SR, Smith R, Hirst JJ, et al., ‘Newcastle 1000 (NEW1000) Study: an Australian population-based prospective pregnancy cohort study design and protocol’, BMJ OPEN, 13 (2023)
  64. Barker, K., Holland, A. E., Skinner, E. & Lee, A. L.,  Clinical outcomes following exercise rehabilitation in people with multimorbidity: a systematic review: Journal of Rehabilitation Medicine. 55, 22 (2023).   
  65. Agusti, A., Ambrosino, N., Blackstock, F., Bourbeau, J., Casaburi, R., Celli, B., Crouch, R., Negro, R. D., Dreher, M., Garvey, C., Gerardi, D., Goldstein, R., Hanania, N., Holland, A. E., Kaur, A., Lareau, S., Lindenauer, P. K., Mannino, D., Make, B., Maltais, F., & 16 others, COPD: Providing the right treatment for the right patient at the right time. Respiratory Medicine. 207 (2023).            
  66. Cox, N. S., Holland, A. E., Jones, A. W., McDonald, C. F., O’Halloran, P., Mahal, A., Hepworth, G. & Lannin, N. A., Implementation of offering choice of pulmonary rehabilitation location to people with COPD: a protocol for the process evaluation of a cluster randomised controlled trial. (2023)
  67. Zanaboni, P., Dinesen, B., Hoaas, H., Wootton, R., Burge, A. T., Philp, R., Oliveira, C. C., Bondarenko, J., Jensen, T. T., Miller, B. R. & Holland, A. E., 1 Apr 2023 Long-term Telerehabilitation or Unsupervised Training at Home for Patients with Chronic Obstructive Pulmonary Disease A Randomized Controlled Trial. In: American Journal of Respiratory and Critical Care Medicine. 207. (2023)
  68. Cox, N. S., Burge, A. T. & Holland, A. E., 2023 Moderate–vigorous physical activity and all-cause mortality in COPD: could bouts matter? ERJ Open Research. 9, 3, 4 p., 00704-2022 (2023).                      
  69. Cox, N. S., Lee, J. Y. T., McDonald, C. F., Mahal, A., Alison, J. A., Wootton, R., Hill, C. J., Zanaboni, P., O’Halloran, P., Bondarenko, J., Macdonald, H., Barker, K., Crute, H., Mellerick, C., Wageck, B., Boursinos, H., Lahham, A., Nichols, A., Czupryn, P., Corbett, M., & 3 others. Perceived Autonomy Support in Telerehabilitation by People With Chronic Respiratory Disease: A Mixed Methods Study (2023).            
  70. Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. (2023)
  71. Rochester, C. L., Alison, J. A., Carlin, B., Jenkins, A. R., Cox, N. S., Bauldoff, G., Bhatt, S. P., Bourbeau, J., Burtin, C., Camp, P. G., Cascino, T. M., Dorney Koppel, G. A., Garvey, C., Goldstein, R., Harris, D., Houchen-Wolloff, L., Limberg, T., Lindenauer, P. K., Moy, M. L., Ryerson, C. J., & et al., American Journal of Respiratory and Critical Care Medicine. 208. (2023).
  72. Neves, L. H. G., Malaguti, C., Santos, M. R., Cabral, L. A., da Silva, L. B. D., de Oliveira, H. H., Brugiolo, A. S. S., José, A., Holland, A. E. & Oliveira, C. C., Pulmonary Telerehabilitation for People With Chronic Obstructive Pulmonary Disease in Brazil: A Mixed-Methods Feasibility Study. (2023).
  73. Green, E. T., Cox, N. S., Arden, C. M., Warren, C. J. & Holland, A. E., What is the effect of a brief intervention to promote physical activity when delivered in a health care setting? A systematic review. Health Promotion Journal of Australia. (2023).
  74. Koh, J., Leong, P. & Bardin, P. G., A new paradigm for vocal cord dysfunction/inducible laryngeal obstruction: Swift diagnosis and streamlined management pathway, Respirology. (2023).
  75. Koh, J., Phyland, D., Ruane, L., Avram, A., Leahy, E., Lau, K. K., MacDonald, M., Leong, P., Baxter, M. & Bardin, P. G. Lessons from a failed randomized controlled trial of speech pathology intervention in vocal cord dysfunction, Respirology (2023)                 
  76. Koh, J., Phyland, D., Baxter, M., Leong, P. & Bardin, P. G., Vocal cord dysfunction/inducible laryngeal obstruction: novel diagnostics and therapeutics. Expert Rev Respir Med. (2023).
  77. Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Harada N, Atsuta R, Fujisawa T, Kawayama T, Inoue H, Lazarus S, Szefler S, Martinez FD, Shaw D, Pavord ID, Thomas M. Fractional exhaled nitric oxide (FeNO): the future of asthma care? The British journal of general practice : the journal of the Royal College of General Practitioners, 73. (2023).
  78. Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, et al. Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks. Am J Respir Crit Care Med; 207(11):1539-42 (2023).
  79. Brown MA, Morgan SB, Donachie GE, Horton KL, Pavord ID, Arancibia-Cárcamo CV, et al. Epithelial immune activation and intracellular invasion by non-typeable Haemophilus influenzae. Front Cell Infect Microbiol; 13:1141798 (2023).
  80. Couillard S, Ducharme FM, Pavord ID. Clinically accessible biomarkers to assess the modifiable risk of asthma/wheezing attacks in toddlers. J Allergy Clin Immunol Pract;11(6):1984-5 (2023).            
  81. Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, et al. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Ann Allergy Asthma Immunol;130(1):60-6 (2023).
  82. Gern JE, Pavord ID. Challenges and Opportunities in Asthma Prevention and Treatment. J Allergy Clin Immunol Pract; 11(3):748-9 (2023).            
  83. Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, et al. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol;130(2):206-14.e2 (2023).                                         
  84. Howell I, Howell A, Pavord ID. Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight. J Exp Med;220 (2023).            
  85. Jackson DJ, Pavord ID. Living without eosinophils: evidence from mouse and man. Eur Respir J;61(1) (2023).                                       
  86. Lavoie G, Pavord ID. Which biologic? New findings from a real-world study. Respirology; 28(12):1091-2. (2023).                                    
  87. Lommatzsch M, Brusselle GG, Levy ML, Canonica GW, Pavord ID, Schatz M, et al. A(2)BCD: a concise guide for asthma management. Lancet Respir Med;11(6):573-6 (2023).
  88. Maspero JF, Shafazand S, Cole J, Pavord ID, Busse WW, Msihid J, et al. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma. Respir Med;218:107344 (2023).                        
  89. Pavord ID, Barnes PJ, Lemière C, Gibson PG. Diagnosis and Assessment of the Asthmas. J Allergy Clin Immunol Pract;11(1):1-8 (2023).
  90. Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract;11(4):1213-20.e2 (2023).
  91. Pavord ID, Hoyte FCL, Lindsley AW, Ambrose CS, Spahn JD, Roseti SL, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann Allergy Asthma Immunol; 131(5):587-97.e3. (2023).
  92. Pavord ID, Tran TN, Jones RC, Nuevo J, van den Berge M, Brusselle GG, et al. Effect of Stepping Up to High-Dose Inhaled Corticosteroids in Patients With Asthma: UK Database Study. J Allergy Clin Immunol Pract;11(2):532-43. (2023).
  93. Petousi N, Pavord ID, Couillard S. The Lancet COPD Commission: broader questions remain. Lancet; 401(10388):1569-70 (2023).
  94. Sher LD, Corren J, Pavord ID, Daizadeh N, Altincatal A, Soler X, et al. Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma. J Asthma; 60(9):1767-74 (2023).
  95. Wang K, Stonham C, Rutherford C, Pavord ID. Fractional exhaled nitric oxide (FeNO): the future of asthma care? Br J Gen Pract; 73(737):565-8 (2023).
  96. Zeng X, Qing J, Li CM, Lu J, Yamawaki T, Hsu YH, et al. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. J Allergy Clin Immunol. 2023;152(4):876-86. (2023).            
  97. Malik B, Bartlett NW, Upham JW, Nichol KS, Harrington J, Wark PAB. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics. Respirology;28(8):758-66 (2023).                                    
  98. Sikder MAA, Rashid RB, Ahmed T, Sebina I, Howard DR, Ullah MA, et al. Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection. Immunity;56(5): 1098-114.e10 (2023)
  99. Upham JW. Can Allergen Immunotherapy Improve Antiviral Immunity in Patients with Allergic Asthma? Am J Respir Crit Care Med; 207(9):1112-4 (2023).                                

2022

  1. McDonald VM, Clark VL, Gibson PG, ‘Nothing about us without us- What matters to patients with severe asthma?‘ J Allergy Clin Immunol Practice, Mar 2022. 1016/j.jaip.2021.11.035
  2. Mathioudakis AG, Abroug F, Agustí A, Ananth S, Bakke P, Bartziokas K, et al., ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Respir J. May2022 1183/13993003.02006-2021
  3. Thomas D, McDonald VM, Pavord ID, Gibson PG, Asthma remission- what is it and how can it be achieved? Eur Respir J. Mar 2022 1183/13993003.02583-2021
  4. McDonald VM, Gibson PG, Treatable traits in asthma: moving beyond diagnostic labels, Medical Journal of Australia. Apr 2022 5694/mja2.51464
  5. Vertigan AE, Bone SL, Gibson PG, The Impact of Functional Laryngoscopy on the Diagnosis of Laryngeal Hypersensitivity Syndromes, J Allergy Clin Immunol Pract. Feb 2022 1016/j.jaip.2021.10.017
  6. Niessen NM, Fricker M, McDonald VM, Gibson PG, T2-low: What do we know? – Past, present, and future of biologic therapies in non-eosinophilic asthma. Ann Allergy Asthma Immunol, Aug 2022 1016/j.anai.2022.04.020
  7. Denton E, Hew M, Gibson PG, Vertigan A. Lone Ranger or Handpicked Posse? How Multidisciplinary Assessment Helps Evaluate Suspected Laryngeal Disorders, J Allergy Clin Immunol Practice. Feb 2022 1016/j.jaip.2021.11.009
  8. Gibson PG. Caging the coughing canary in the global lung health coal mine, Jan 2022 10.1111/resp.14190
  9. Baggott C, Hardy JK, Sparks J, Sabbagh D, Beasley R, Weatherall M, Fingleton J. Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis, Jun 2022 10.1136/thoraxjnl-2021-217124
  10. Cox NS, McDonald CF, Mahal A, Alison JA, Wootton R, Hill CJ, Zanaboni P, O’Halloran P, Bondarenko J, Macdonald H, Barker K, Crute H, Mellerick C, Wageck B, Boursinos H, Lahham A, Nichols A, Czupryn P, Corbett M, Handley E, Burge AT, Holland AE. Telerehabilitation for chronic respiratory disease: a randomised controlled equivalence trial, Thorax. Jul 2022 1136/thoraxjnl-2021-216934
  11. Douglass JA, Lodge C, Chan S, Doherty A, Tan JA, Jin C, Stewart A, Southcott AM, Gillman A, Lee J, Csutoros D, Hannan L, Ruane L, Barnes S, Irving L, Harun NS, Lachapelle P, Spriggs K, Sutherland M, See K, McDonald CF, Conron M, Radhakrishna N, Worsnop C, Johnston FH, Davies JM, Bryant V, Iles L, Ranson D, Spanos P, Vicendese D, Lowe A, Newbigin EJ, Bardin P, Dharmage S. Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study, Journal of Allergy & Clinical Immunology. May 2022 1016/j.jaci.2021.10.028
  12. Bush A, Pavord ID. Reply to: Challenging the paradigm; moving from umbrella labels to treatable traits in airway disease, Breathe. Mar 2022 1183/20734735.0174-2021
  13.  Melhorn J, Howell I, Pavord ID. Should we apply a treatable traits approach to asthma care? Annals of Allergy, Asthma & Immunology. Apr 2022 1016/j.anai.2022.02.005
  14. Foster J, Beasley R, Braithwaite I, Harrison T, Holliday M, Pavord I, Reddel H. Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study, BMJ Open. Jan 2022 1136/bmjopen-2020-048537
  15. Thomas D, Gibson PG. Gefapixant for chronic cough, The Lancet. Mar 2022 1016/S0140-6736(21)02438-7
  16. Beasley R, Harrison T, Peterson S, Gustafson P, Hamblin A, Bengtsson T, Fagerås M. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients with Poorly Controlled Asthma: A Systematic Review and Meta-analysis, Jama Network Open. Mar 2022 1001/jamanetworkopen.2022.0615
  17. Jackson DJ, Akuthota P, Andradas R, Bredenoord AJ, Cordell A, Gray S, Kullman J, Mathur SK, Pavord I, Roufosse F, Rubio C, Rusek IC, Simon D, Strobel MJ, Winders T.   Improving Care in Eosinophil-Associated Diseases: A Charter. Adv Ther. 2022. 10.1007/s12325-022-02110-8
  18. Hancock KL, Bosnic-Anticevich S, Blakey JD, Hew M, Chung LP, Cvetkovski B, Claxton S, Del Fante P, Denton E, Doan J, Ranasinghe K, Morgan L, Sharma A, Smith PK, Stewart D, Thompson PJ, Wiseman R, Upham JW, Yan KY, Carter V, Dhillon K, Heraud F, Le T, Vella R, Price D; Improving Asthma outcomes in Australia Research Group.   Characterisation of the Australian Adult Population Living with Asthma: Severe – Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.  Pragmat Obs Res. 2022. 10.2147/POR.S360044 
  19. Scott HA, Wood LG, Williams EJ, Weaver N, Upham JW.  Comparing the Effect of Acute Moderate and Vigorous Exercise on Inflammation in Adults with Asthma: A Randomized Controlled Trial. Ann Am Thorac Soc. 2022. 10.1513/AnnalsATS.202109-1053OC
  20. McDonald VM, Gibson PG. Treatable Traits in Asthma and COPD. Arch Bronconeumol. 2022. 10.1016/j.arbres.2021.07.003
  21. Godbout K, Gibson PG.  Defining Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am.  2022. 10.1016/j.iac.2022.04.007
  22. Gibson PG. Adding some NOVELTY to treatable traits.  Respirology. 2022. 0.1111/resp.14341
  23. Da Silva Sena CR, Lines O, Latheef MS, Amarasinghe GG, Quah WH, Beyene T, Van Buskirk J, Hanigan I, Morgan G, Oldmeadow C, Gibson PG, Murphy VE, de Waal K, Karmaus W, Platt L, Pearce K, Collison AM, Mattes J. Eduction in forced vital capacity in asthmatic children on days with bushfire smoke exposure in the Australian 2019/2020 bushfire. Pediatr Allergy Immunol. 2022. 10.1111/pai.13872
  24. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Resp Journal. 2022. 10.1183/13993003.02583-2021
  25. Zhang S, Zhang X, Deng K, Wang C, Wood LG, Wan H, Liu L, Wang J, Zhang L, Liu Y, Cheng G, Gibson PG, Oliver BG, Luo F, McDonald VM, Li W, Wang G. Reduced Skeletal Muscle Mass Is Associated with an Increased Risk of Asthma Control and Exacerbation. J Clin Med. 2022 10.3390/jcm11237241
  26. Beyene T, Murphy VE, Gibson PG, McDonald VM, Van Buskirk J, Holliday EG, Vertigan AE, Horvat JC, Zosky GR, Morgan GG, Jegasothy E, Hanigan I, Mattes J, Collison AM, Jensen ME. The impact of prolonged landscape fire smoke exposure on women with asthma in Australia BMC Pregnancy Childbirth. 2022. 10.1186/s12884-022-05231-8
  27. Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. Resp Research. 2022. 10.1186/s12931-022-02266-5
  28. Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG; Australian Mepolizumab Registry Investigators. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract 2022. 10.1016/j.jaip.2022.12.004
  29. Leong P, Vertigan AE, Hew M, Baxter M, Phyland D, Hull JH, Carroll TL, Gibson PG, McDonald VM, Bardin PG. Diagnosis of vocal cord dysfunction / inducible laryngeal obstruction-A Delphi study protocol. PloS One. 2022
  30. Holland AE, Wageck B, Hoffman M, Lee AL, Jones AW. Does pulmonary rehabilitation address treatable traits? A systematic review. Eur Respir J. 2022. 10.1183/16000617.0042-2022
  31. Pavord ID. Case-finding and diagnosis of obstructive airway diseases: the Dragons’ Den experience. Eur Respir J. 2022. 10.1183/13993003.00679-2022
  32. Chen S, Miravitlles M, Rhee CK, Pavord ID, Jones R, Carter V, Emmanuel B, Alacqua M, Price DB. Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis. 2022. 10.2147/COPD.S378649
  33. Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype. J Allergy Clin Immunol Pract 2022. 10.1016/j.jaip.2022.06.036
  34. Upham, JW. Home Administration of Biologics for Severe Asthma-A Good Option for Some but Not All. J Allergy Clin Immunol Pract, 2022.  10.1016/j.jaip.2022.06.007
  35. Agustí A, Rapsomaniki E, Beasley R, Hughes R, Müllerová H, Papi A, Pavord ID, van den Berge M, Faner R; NOVELTY Study Investigators.  Treatable traits in the NOVELTY study. Respirology. 2022 10.1111/resp.14325
  36. Holland AE, Bondarenko J. Breathlessness: Remembering the worst of it.  Respirology. 2022 10.1111/resp.14329
  37. Cox NS, Holland AE. Gambling on Pulmonary Rehabilitation: What Are the Odds of Being Referred? Chest. 2022. 10.1016/j.chest.2022.02.033
  38. Yang F, Busby J, Heaney LG, Pavord ID, Brightling CE, Borg K, McDowell JP, Diver SE, Shrimanker R, Bradding P, Shepherd M, Chaudhuri R; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma – a randomised, placebo-controlled crossover trial. J Allergy Clin Immunol Pract2022. 10.1016/j.jaip.2022.06.050
  39. Li M, Wen Ma Z, Jun Deng S, Oliver BG, Wang T, Ping Zhang H, Wang L, McDonald VM, Wang J, Liu D, Gibson PG, Ming Luo F, Min Li W, Jing Wan H, Wang G.         Development and validation of a non-invasive prediction model for identifying eosinophilic asthma. Respir Med 2022. 10.1016/j.rmed.2022.106935
  40. McLoughlin RF, Clark VL, Urroz PD, Gibson PG, McDonald VM. Increasing physical activity in severe asthma: a systematic review and meta-analysis.  Eur Resp J. 2022. 0.1183/13993003.00546-2022
  41. Xiao W, Du L, Cai L, Miao T, Mao B, Wen F, Gibson PG, Gong D, Zeng Y, Kang M, Du X, Qu J, Wang Y, Liu X, Feng R, Fu J. Existing tests vs. novel non-invasive assays for detection of invasive aspergillosis in patients with respiratory diseases. Chin Med J. 2022. 10.1097/CM9.0000000000002050.
  42. Pitzner-Fabricius A, Clark VL, Backer V, Gibson PG, McDonald VM. Factors associated with 6-min walk distance in severe asthma: A cross-sectional study. Respirology 2022. 10.1111/resp.14323
  43. Thomas D, Gibson PG.   Long-Term, Low-Dose Azithromycin for Uncontrolled Asthma in Children. Chest. 2022. 10.1016/j.chest.2022.03.035
  44. Liu L, Zhang X, Zhang L, Liu Y, Zhang HP, Zhao SZ, Zhang J, Zhang WJ, Wang F, Wang L, Zhou AX, Li WM, Wang G, Gibson PG. Reduced bronchodilator reversibility correlates with non-type 2 high asthma and future exacerbations: A prospective cohort study. Respir Med. 2022. 10.1016/j.rmed.2022.106924
  45. Sánchez-Ovando S, Pavlidis S, Kermani NZ, Baines KJ, Barker D, Gibson PG, Wood LG, Adcock IM, Chung KF, Simpson JL, Wark PAB. Pathways linked to unresolved inflammation and airway remodelling characterize the transcriptome in two independent severe asthma cohorts. Respirology 2022 10.1111/resp.14302
  46. Deng SJ, Wang J, Liu L, Zhang X, Gibson PG, Chen ZH, Birring SS, Xie M, Lai KF, Qin L, Liu D, Vertigan AE, Song WJ, McGarvey L, Luo FM, Chung KF, Li WM, Wang G. Chronic cough in asthma is associated with increased airway inflammation, more comorbidities, and worse clinical outcomes. Asthma Allergy Proc. 2022. 10.2500/aap.2022.43.220022.
  47. Niessen NM, Fricker M, McDonald VM, Gibson PG. T2-low: what do we know?: Past, present, and future of biologic therapies in non-eosinophilic asthma.  Ann Allergy Asthma Immunology. 2022. 10.1016/j.anai.2022.04.020
  48. Ali H, Brooks C, Tzeng YC, Crane J, Beasley R, Gibson P, Pattemore P, Stanley T, Pearce N, Douwes J. Heart rate variability as a marker of autonomic nervous system activity in young people with eosinophilic and non-eosinophilic asthma. J of Asthma. 2022. 10.1080/02770903.2022.2070763
  49. Liu Y, Zhang X, Zhang L, Oliver BG, Wang HG, Liu ZP, Chen ZH, Wood L, Hsu AC, Xie M, McDonald V, Wan HJ, Luo FM, Liu D, Li WM, Wang G. Sputum Metabolomic Profiling Reveals Metabolic Pathways and Signatures Associated With Inflammatory Phenotypes in Patients With Asthma. Asthma Allergy Immun Res. 2022. 10.4168/aair.2022.14.4.393
  50. Mathioudakis AG, Abroug F, Agusti A, Ananth S, Bakke P, Bartziokas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner GJ, Csoma B, Emelyanov A, Faner R, Fernandez Romero G, Hammouda Z, Horváth P, Huerta Garcia A, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, Linnell J, López-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen JU; DECODE-NET. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.’ Eur Resp J. 2022. 10.1183/13993003.02006-2021
  51. Thomas D, McDonald VM, Simpson JL, Smith A, Gupta S, Majellano E, Gibson PG. Patterns of azithromycin use in obstructive airway diseases: a real-world observational study. Intern Med J 2022.  10.1111/imj.15216
  52. Golam SM, Janson C, Beasley R, FitzGerald JM, Harrison T, Chipps B, Hughes R, Müllerová H, Olaguibel JM, Rapsomaniki E, Reddel HK, Sadatsafavi M; NOVELTY investigators.   The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. Resp Med. 2022. 10.1016/j.rmed.2022.106863
  53. Kearns N, Williams M, Bruce P, Black M, Kearns C, Sparks J, Braithwaite I, Weatherall M, Beasley R. Single dose of budesonide/formoterol turbuhaler compared to salbutamol pMDI for speed of bronchodilator onset in asthma: a randomised cross-over trial. Thorax. 2022. 10.1136/thorax-2022-219052.
  54. Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. Pulm Pharmacol Ther. 2022. 10.1016/j.pupt.2022.102133
  55. Murphy VE. Asthma in pregnancy – Management, maternal co-morbidities, and long-term health. Best Pract Res Clin Obstet Gynaecol 2022. 10.1016/j.bpobgyn.2022.06.005.
  56. Brew BK, Gibberd A, Marks GB, Murphy VE, Jorm L, Chambers GM, Hartz D, Eades S, McNamara B. Maternal asthma in Australian indigenous women and perinatal outcomes: A whole population-linked study. Int J Gynaecol Obstet. 2022. 10.1002/ijgo.14363
  57. Murphy VE, Jensen ME, Holliday EG, Giles WB, Barrett HL, Callaway LK, Bisits A, Peek MJ, Seeho SK, Abbott A, Robijn AL, Colditz PB, Searles A, Attia J, McCaffery K, Hensley MJ, Mattes J, Gibson PG. Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes. Eur Resp J. 2022. 10.1183/13993003.00298-2022.
  58. Robijn AL, Bokern MP, Jensen ME, Barker D, Baines KJ, Murphy VE. Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis.  Eur Resp Rev 2022. 10.1183/16000617.0039-2022
  59. Wright TK, McLaughlin K, Jensen ME, Robijn AL, Foureur M, Murphy VE. A cross-sectional survey of Australian healthcare professionals’ confidence, evidence-based knowledge and guideline use for antenatal asthma management. Aust NZ J Obstet Gynaecol. 2022. 10.1111/ajo.13525
  60. McLaughlin K, Jensen M, Foureur M, Murphy VE. Are pregnant women with asthma receiving guideline-recommended antenatal asthma management? A survey of pregnant women receiving usual care in Australia. Women Birth. 2022. 10.1016/j.wombi.2022.03.008
  61. Alsubheen SA, Beauchamp MK, Ellerton C, Goldstein R, Alison JA, Dechman G, Haines KJ, Harrison SL, Holland AE, Lee AL, Marques A, Spencer L, Stickland M, Skinner EH, Brooks D. Validity of the Activities-specific Balance Confidence Scale in individuals with chronic obstructive pulmonary disease. Expert Rev Respir Med. 2022. 10.1080/17476348.2022.2099378
  62. Holland AE, Jones AW, Mahal A, Lannin NA, Cox N, Hepworth G, O’Halloran P, McDonald CF. Implementing a choice of pulmonary rehabilitation models in chronic obstructive pulmonary disease (HomeBase2 trial): protocol for a cluster randomised controlled trial. BMJ Open 2022 10.1136/bmjopen-2021-057311
  63. Alsubheen SA, Beauchamp M, Ellerton C, Goldstein R, Alison J, Dechman G, Haines KJ, Harrison S, Holland A, Lee A, Marques A, Spencer L, Stickland M, Skinner EH, Brooks D. Age and Sex Differences in Balance Outcomes among Individuals with Chronic Obstructive Pulmonary Disease (COPD) at Risk of Falls.     COPD. 2022. 10.1080/15412555.2022.2038120
  64. Jackson DJ, Pavord ID.   Living without eosinophils: evidence from mouse and man. Eur Respir J. 2022. 10.1183/13993003.01217-2022
  65. Smith JA, Birring SS, Dicpinigaitis PV, McGarvey LP, Morice AH, Pavord ID, Satia I, Green S, Iskold B, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Muccino D. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. Lung. 2022. 10.1007/s00408-022-00553-y
  66. Couillard S, Shrimanker R, Lemaire-Paquette S, Hynes GM, Borg C, Connolly C, Thulborn SJ, Moran A, Poole S, Morgan S, Powell T, Pavord I, Hinks T.  Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Thorax. 2022. 10.1136/thoraxjnl-2021-217994
  67. Diver S, Haldar K, McDowell PJ, Busby J, Mistry V, Micieli C, Brown V, Cox C, Yang F, Borg C, Shrimanker R, Ramsheh MY, Hardman T, Arron J, Bradding P, Cowan D, Mansur AH, Fowler SJ, Lordan J, Menzies-Gow A, Robinson D, Matthews J, Pavord ID, Chaudhuri R, Heaney LG, Barer MR, Brightling C; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy 2022. 10.1111/all.15425
  68. Khalfaoui L, Symon FA, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, Mansur AH, Shrimanker R, Hinks TSC, Pavord ID, Fowler SJ, Brown V, McGarvey LP, Heaney LG, Austin CD, Howarth PH, Arron JR, Choy DF, Bradding P.  Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma. Allergy 2022. 10.1111/all.15376
  69. Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, Satia I, Smith JA, La Rosa C, Li Q, Nguyen AM, Schelfhout J, Tzontcheva A, Muccino D. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.  Ann Allergy Asthma Immunology. 2022. 10.1016/j.anai.2022.05.003
  70. McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan D, Mansur AH, Fowler SJ, Diver SE, Howarth P, Lordan J, Menzies-Gow A, Harrison T, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, Heaney LG; investigators for the MRC Refractory Asthma Stratification Program.  Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population. Am J Respir Crit Care Med, 2022 10.1164/rccm.202201-0129
  71. Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, Yancey SW. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.             ERJ Open Res, 2022 10.1183/23120541.00560-2021
  72. Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of Interventions Targeting Treatable Traits for the Management of Obstructive Airway Diseases: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. May 2022.Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of Interventions Targeting Treatable Traits for the Management of Obstructive Airway Diseases: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. May 2022.
  73. Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of Interventions Targeting Treatable Traits for the Management of Obstructive Airway Diseases: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. May 2022.
  74. Agustí A, Rapsomaniki E, Beasley R, Hughes R, Müllerová H, Papi A, Pavord ID, van den Berge M, Faner R; NOVELTY Study Investigators.
  75. Treatable traits in the NOVELTY study. Respirology. July 2022.
  76. Holland AE, Bondarenko J. Breathlessness: Remembering the worst of it. Respirology. July 2022.
  77. Cox NS, Holland AE. Gambling on Pulmonary Rehabilitation: What Are the Odds of Being Referred? Chest. July 2022.
  78. Yang F, Busby J, Heaney LG, Pavord ID, Brightling CE, Borg K, McDowell JP, Diver SE, Shrimanker R, Bradding P, Shepherd M, Chaudhuri R; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma – a randomised, placebo-controlled crossover trial [MAPLE]. J Allergy Clin Immunol Pract. July 2022.
  79. Li M, Wen Ma Z, Jun Deng S, Oliver BG, Wang T, Ping Zhang H, Wang L, McDonald VM, Wang J, Liu D, Gibson PG, Ming Luo F, Min Li W, Jing Wan H, Wang G. Development and validation of a non-invasive prediction model for identifying eosinophilic asthma. Respir Med. July 2022.
  80. McLoughlin RF, Clark VL, Urroz PD, Gibson PG, McDonald VM. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Resp J. July 2022.
  81. Xiao W, Du L, Cai L, Miao T, Mao B, Wen F, Gibson PG, Gong D, Zeng Y, Kang M, Du X, Qu J, Wang Y, Liu X, Feng R, Fu J. Existing tests vs. novel non-invasive assays for detection of invasive aspergillosis in patients with respiratory diseases. Chin Med J. July 2022.
  82. Pitzner-Fabricius A, Clark VL, Backer V, Gibson PG, McDonald VM. Factors associated with 6-min walk distance in severe asthma: A cross-sectional study. Respirology. July 2022.
  83. Thomas D, Gibson PG. Age and Sex Differences in Balance Outcomes among Individuals with Chronic Obstructive Pulmonary Disease (COPD) at Risk of Falls. Chest. July 2022.
  84. Liu L, Zhang X, Zhang L, Liu Y, Zhang HP, Zhao SZ, Zhang J, Zhang WJ, Wang F, Wang L, Zhou AX, Li WM, Wang G, Gibson PG. Reduced bronchodilator reversibility correlates with non-type 2 high asthma and future exacerbations: A prospective cohort study. Respir Med. June 2022.
  85. Sánchez-Ovando S, Pavlidis S, Kermani NZ, Baines KJ, Barker D, Gibson PG, Wood LG, Adcock IM, Chung KF, Simpson JL, Wark PAB. Pathways linked to unresolved inflammation and airway remodelling characterize the transcriptome in two independent severe asthma cohorts. Respirology. June 2022.
  86. Deng SJ, Wang J, Liu L, Zhang X, Gibson PG, Chen ZH, Birring SS, Xie M, Lai KF, Qin L, Liu D, Vertigan AE, Song WJ, McGarvey L, Luo FM, Chung KF, Li WM, Wang G. Chronic cough in asthma is associated with increased airway inflammation, more comorbidities, and worse clinical outcomes.  Asthma Allergy Proc. May 2022.
  87. Khalfaoui L, Symon FA, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, Mansur AH, Shrimanker R, Hinks TSC, Pavord ID, Fowler SJ, Brown V, McGarvey LP, Heaney LG, Austin CD, Howarth PH, Arron JR, Choy DF, Bradding P. Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma. Allergy. May 2022.
  88. Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, Satia I, Smith JA, La Rosa C, Li Q, Nguyen AM, Schelfhout J, Tzontcheva A, Muccino D. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Ann Allergy Asthma Immunology. May 2022.
  89. Ali H, Brooks C, Tzeng YC, Crane J, Beasley R, Gibson P, Pattemore P, Stanley T, Pearce N, Douwes J. Heart rate variability as a marker of autonomic nervous system activity in young people with eosinophilic and non-eosinophilic asthma. J of Asthma. May 2022.
  90. Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, Yancey SW. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Res. May 2022.
  91. McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, Brightling CE, Chaudhuri R, Cowan D, Mansur AH, Fowler SJ, Diver SE, Howarth P, Lordan J, Menzies-Gow A, Harrison T, Robinson DS, Holweg CTJ, Matthews JG, Pavord ID, Heaney LG; investigators for the MRC Refractory Asthma Stratification Program. Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population. Am J Respir Crit Care Med. May 2022.
  92. Niessen NM, Fricker M, McDonald VM, Gibson PG. T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma. Ann Allergy Asthma Immunology. Aug 2022.
  93. Liu Y, Zhang X, Zhang L, Oliver BG, Wang HG, Liu ZP, Chen ZH, Wood L, Hsu AC, Xie M, McDonald V, Wan HJ, Luo FM, Liu D, Li WM, Wang G. Sputum Metabolomic Profiling Reveals Metabolic Pathways and Signatures Associated With Inflammatory Phenotypes in Patients With Asthma. Asthma Allergy Immun Resp. July 2022.
  94. Mathioudakis AG, Abroug F, Agusti A, Ananth S, Bakke P, Bartziokas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner GJ, Csoma B, Emelyanov A, Faner R, Fernandez Romero G, Hammouda Z, Horváth P, Huerta Garcia A, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, Linnell J, López-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen JU; DECODE-NET. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Resp J. May 2022.
  95. Thomas D, McDonald VM, Simpson JL, Smith A, Gupta S, Majellano E, Gibson PG. Patterns of azithromycin use in obstructive airway diseases: a real-world observational study. Intern Med J. June 2022.
  96. Golam SM, Janson C, Beasley R, FitzGerald JM, Harrison T, Chipps B, Hughes R, Müllerová H, Olaguibel JM, Rapsomaniki E, Reddel HK, Sadatsafavi M; NOVELTY investigators. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. Resp Med. May 2022.
  97. Kearns N, Williams M, Bruce P, Black M, Kearns C, Sparks J, Braithwaite I, Weatherall M, Beasley R. Single dose of budesonide/formoterol turbuhaler compared to salbutamol pMDI for speed of bronchodilator onset in asthma: a randomised cross-over trial. Thorax. July 2022.
  98. Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. Pulm Pharmacol Ther. Aug 2022.
  99. Murphy VE. Asthma in pregnancy – Management, maternal co-morbidities, and long-term health. Best Pract Res Clin Obstet Gynaecol. June 2022.
  100. Brew BK, Gibberd A, Marks GB, Murphy VE, Jorm L, Chambers GM, Hartz D, Eades S, McNamara B. Maternal asthma in Australian indigenous women and perinatal outcomes: A whole population-linked study. Int J Gynaecol Obstet. July 2022.
  101. Murphy VE, Jensen ME, Holliday EG, Giles WB, Barrett HL, Callaway LK, Bisits A, Peek MJ, Seeho SK, Abbott A, Robijn AL, Colditz PB, Searles A, Attia J, McCaffery K, Hensley MJ, Mattes J, Gibson PG. Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes. Eur Resp J. July 2022.
  102. Robijn AL, Bokern MP, Jensen ME, Barker D, Baines KJ, Murphy VE. Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis. Eur Resp Rev. June 2022.
  103. Wright TK, McLaughlin K, Jensen ME, Robijn AL, Foureur M, Murphy VE. A cross-sectional survey of Australian healthcare professionals’ confidence, evidence-based knowledge and guideline use for antenatal asthma management. Aust NZ J Obstet Gynaecol. Apr 2022.
  104. Alsubheen SA, Beauchamp MK, Ellerton C, Goldstein R, Alison JA, Dechman G, Haines KJ, Harrison SL, Holland AE, Lee AL, Marques A, Spencer L, Stickland M, Skinner EH, Brooks D. Validity of the Activities-specific Balance Confidence Scale in individuals with chronic obstructive pulmonary disease. Expert Rev Respir Med. Jun 2022.
  105. Holland AE, Jones AW, Mahal A, Lannin NA, Cox N, Hepworth G, O’Halloran P, McDonald CF. Implementing a choice of pulmonary rehabilitation models in chronic obstructive pulmonary disease (HomeBase2 trial): protocol for a cluster randomised controlled trial. Apr 2022.
  106. Jackson DJ, Pavord ID. Living without eosinophils: evidence from mouse and man. Eur Respir J. Aug 2022.
  107. Smith JA, Birring SS, Dicpinigaitis PV, McGarvey LP, Morice AH, Pavord ID, Satia I, Green S, Iskold B, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Muccino D. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. Lung. Aug 2022.
  108. Couillard S, Shrimanker R, Lemaire-Paquette S, Hynes GM, Borg C, Connolly C, Thulborn SJ, Moran A, Poole S, Morgan S, Powell T, Pavord I, Hinks T. Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Thorax. Jul 2022.
  109. Diver S, Haldar K, McDowell PJ, Busby J, Mistry V, Micieli C, Brown V, Cox C, Yang F, Borg C, Shrimanker R, Ramsheh MY, Hardman T, Arron J, Bradding P, Cowan D, Mansur AH, Fowler SJ, Lordan J, Menzies-Gow A, Robinson D, Matthews J, Pavord ID, Chaudhuri R, Heaney LG, Barer MR, Brightling C; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy. July 2022.
  110. Jackson DJ, Akuthota P, Andradas R, Bredenoord AJ, Cordell A, Gray S, Kullman J, Mathur SK, Pavord I, Roufosse F, Rubio C, Rusek IC, Simon D, Strobel MJ, Winders T. Improving Care in Eosinophil-Associated Diseases: A Charter. Advances in Therapy. Jun 2022.
  111. Hancock KL, Bosnic-Anticevich S, Blakey JD, Hew M, Chung LP, Cvetkovski B, Claxton S, Del Fante P, Denton E, Doan J, Ranasinghe K, Morgan L, Sharma A, Smith PK, Stewart D, Thompson PJ, Wiseman R, Upham JW, Yan KY, Carter V, Dhillon K, Heraud F, Le T, Vella R, Price D; OPCA Improving Asthma outcomes in Australia Research Group. Characterisation of the Australian Adult Population Living with Asthma: Severe – Exacerbation Frequency, Long-Term OCS Use and Adverse Effects. Pragmat Obs Res. Jul 2022.
  112. Scott HA, Wood LG, Williams EJ, Weaver N, Upham JW. Comparing the Effect of Acute Moderate and Vigorous Exercise on Inflammation in Adults with Asthma: A Randomized Controlled Trial. Ann Am Thorac Soc. Jul 2022.
  113. McDonald VM, Gibson PG. Treatable Traits in Asthma and COPD. Arch Bronconeumol. Aug 2022.
  114. Godbout K, Gibson PG. Defining Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. Aug 2022.
  115. Gibson PG. Adding some NOVELTY to treatable traits. Respirology. Nov 2022.
  116. Da Silva Sena CR, Lines O, Latheef MS, Amarasinghe GG, Quah WH, Beyene T, Van Buskirk J, Hanigan I, Morgan G, Oldmeadow C, Gibson PG, Murphy VE, de Waal K, Karmaus W, Platt L, Pearce K, Collison AM, Mattes J. Reduction in forced vital capacity in asthmatic children on days with bushfire smoke exposure in the Australian 2019/2020 bushfire. Pediatr Allergy Immunol. Nov 2022.
  117. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Resp Journal. Nov 2022.
  118. Zhang S, Zhang X, Deng K, Wang C, Wood LG, Wan H, Liu L, Wang J, Zhang L, Liu Y, Cheng G, Gibson PG, Oliver BG, Luo F, McDonald VM, Li W, Wang G. Reduced Skeletal Muscle Mass Is Associated with an Increased Risk of Asthma Control and Exacerbation. J Clin Med. Dec 2022.
  119. Beyene T, Murphy VE, Gibson PG, McDonald VM, Van Buskirk J, Holliday EG, Vertigan AE, Horvat JC, Zosky GR, Morgan GG, Jegasothy E, Hanigan I, Mattes J, Collison AM, Jensen ME. The impact of prolonged landscape fire smoke exposure on women with asthma in Australia. BMC Pregnancy Childbirth. Dec 2022.
  120. Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. Resp Research. Dec 2022.
  121. Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG; Australian Mepolizumab Registry Investigators. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. Dec 2022.
  122. Leong P, Vertigan AE, Hew M, Baxter M, Phyland D, Hull JH, Carroll TL, Gibson PG, McDonald VM, Bardin PG. Diagnosis of vocal cord dysfunction / inducible laryngeal obstruction-A Delphi study protocol. PloS One. Dec 2022.
  123. Holland AE, Wageck B, Hoffman M, Lee AL, Jones AW. Does pulmonary rehabilitation address treatable traits? A systematic review. Eur Respir J. Aug 2022.
  124. Cox NS, Lee JYT, McDonald CF, Mahal A, Alison JA, Wootton R, Hill CJ, Zanaboni P, O’Halloran P, Bondarenko J, Macdonald H, Barker K, Crute H, Mellerick C, Wageck B, Boursinos H, Lahham A, Nichols A, Czupryn P, Corbett M, Handley E, Burge AT, Holland AE.   Perceived Autonomy Support in Telerehabilitation by People With Chronic Respiratory Disease: A Mixed Methods Study. Chest. Dec 2022.
  125. Pavord ID. Case-finding and diagnosis of obstructive airway diseases: the Dragons’ Den experience. Eur Respir J. Sep 2022.
  126. Chen S, Miravitlles M, Rhee CK, Pavord ID, Jones R, Carter V, Emmanuel B, Alacqua M, Price DB. Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis. Sep 2022.
  127. Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype. J Allergy Clin Immunol Pract. Nov 2022

2021

  1. Freitas PD, Passos NFP, Carvalho-Pinto RM, Martins MA, Cavalheri V, Hill K, Stelmach R, Carvalho CRF. A Behaviour Change Intervention Aimed at Increasing Physical Activity Improves Clinical Control in Adults With Asthma: A Randomized Controlled Trial, Jan 2021 10.1016/j.chest.2020.08.2113
  2. Freitas PD, Xavier RF, McDonald VM, Gibson PG, Cordova-Rivera L, Furlanetto KC, et al., Identification of asthma phenotypes based on extrapulmonary treatable traits, Euro Respiratory Journal. Jan 2021 1183/13993003.00240-2020
  3. Fergus W. Gardiner, Alice Richardson, Carly Roxburgh, Marianne Gillam, Leonid Churilov, Ruth McCuaig, Sean Carter, Christopher Arthur, Cynthia Wong, Adam Morton, Leonie Callaway, Karin Lust, Sarah J. Davidson, Katie Foxcroft, Kiri Oates, Lucy Zhang, Sahani Jayawardane, Mathew Coleman, Michael Peek. Characteristics and in-hospital outcomes of patients requiring aeromedical retrieval for pregnancy, compared to non-retrieved metropolitan cohorts, ANZJOG. Jan 2021 1111/ajo.13308
  4. O’Neill C, Gibson PG, Heaney L, Upham JW, Yang I, Reynolds P, Hodge S, Jenkins C, Peters M, Marks GB, James AL, Simpson J. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma, Euro Respir J. Feb 2021 1183/13993003.02436-2020
  5. Vertigan AE, Kapela SL, Gibson PG. Laryngeal Dysfunction in Severe Asthma: A Cross-Sectional Observational Study. J Allergy Clin Immunol Pract. Feb 2021 1016/j.jaip.2020.09.034
  6. Vanessa M McDonald, Paola D Urroz, Marika Bajc, Natalie Rutherford, Bree Brooker, Peter G Gibson. Imaging for Precision Medicine: Can V-P SPECT measure Mepolizumab Response in Asthma? Respirology Case Reports. Feb 2021 1002/rcr2.717
  7. Sarah A Hiles, Paola D Urroz, Peter G Gibson, Adam Bogdanovs, Vanessa M McDonald. A feasibility randomised controlled trial of Novel Activity Management in severe ASthma – Tailored Exercise (NAMASTE): Yoga and Mindfulness. BMC Resp Open. Feb 2021 1186/s12890-021-01436-3
  8. Xin Zhang, Li Zhang, Rui Liang, Vanessa M McDonald, Hong Ping Zhang, He Yu, Zong An Liang, Lei Wang, Guy B Marks, Wei Min Li, Gang Wang, Peter G Gibson. Clinical phenotypes of patients hospitalized for an asthma exacerbation: prognostic implications. J Allergy Clin Immunol Pract. Feb 2021 1016/j.jaip.2020.09.031
  9. Hew M, Denton E. Prioritizing Treatable Traits in Airways Disease. J Allergy Clin Immunol Pract. Mar 2021 1016/j.jaip.2020.11.012
  10. Sarah A. Hiles, Peter G. Gibson, Alvar Agustí, Vanessa M. McDonald. Treatable Traits That Predict Health Status and Treatment Response in Airway Disease. J Allergy Clin Immunol Pract. Mar 2021 1016/j.jaip.2020.09.046
  11. Robijn AL, Barker D, Gibson PG, Giles WB, Clifton VL, Mattes J, Peek MJ, Barrett HL, Seeho SK, Callaway LK, Abbott A, Attia J, Wark PA, Jensen ME, Murphy VE. Factors Associated with Nonadherence to Inhaled Corticosteroids for Asthma During Pregnancy. J Allergy Clin Immunol Pract. Mar 2021 1016/j.jaip.2020.09.045
  12. Natasha Winter, Peter G Gibson, Michael Fricker, Jodie L Simpson, Peter AB Wark, Vanessa M McDonald. Hemopexin: a novel anti-inflammatory diagnostic marker in chronic airway disease. Allergy Asthma Immunol Res. May 2021 4168/aair.2021.13.3.450
  13. Laura Cordova-Rivera, Paul A.Gardiner, Peter G.Gibson, Elisabeth A.H.Winkler, Paola D.Urroz, Vanessa M.McDonald. Sedentary time in people with obstructive airway diseases. Respiratory Medicine. May 2021 1016/j.rmed.2021.106367
  14. McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respiratory Medicine. May 2021 1016/S2213-2600(21)00004-7
  15. Pham J, Hew M, Dharmage SC. Is ethnicity a ‘treatable trait’ in asthma? Jun 2021 10.1111/resp.14058
  16. Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respiratory Medicine. Jun 2021 1186/s12931-021-01746-4
  17. Murphy RC, Pavord ID, Alam R, Altman MC. Management Strategies to Reduce Exacerbations in non-T2 Asthma. J Allergy Clin Immunol. Jul 2021 1016/j.jaip.2021.04.033
  18. Michael Fricker, Vanessa M. McDonald, Natasha A. Winter, Katherine J. Baines, Peter A.B. Wark, Jodie L. Simpson, Peter G. Gibson. Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic COPD. Allergy. Jul 2021 1111/all.14741
  19. Shukla SD, Taylor SL, Gibson PG, Barker D, Upham JW, Yang IA, Reynolds PN, Hodge S, James AL, Rogers GB, Simpson JL. Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. Thorax. Jul 2021 1136/thoraxjnl-2020-216331
  20. Murphy VE, Karmaus W, Mattes J, Brew BK, Collison A, Holliday E, Jensen ME, Morgan GG, Zosky GR, McDonald VM, Jegasothy E, Robinson PD, Gibson PG. Exposure to Stress and Air Pollution from Bushfires during Pregnancy: Could Epigenetic Changes Explain Effects on the Offspring? Int J Environ Res Public Health. Jul 2021 3390/ijerph18147465
  21. Niessen N, Gibson P, K.J. B, Barker D, Yang I, Upham J, P. R, Hodge S, James A, Jenkins C, Peters M, Mark G, Baraket M, Simpson J, Fricker M. Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. Allergy. Jul 2021 1111/all.14768
  22. Wen Wen Wu, Xin Zhang, Min Li, Ying Liu, Zhi Hong Chen, Min Xie, Shu Zhen Zhao, Gang Wang, Hong Ping Zhang, Ting Wang, Ling Qin, Lei Wang, Brian G. Oliver, Hua Jing Wan, Jie Zhang, Vanessa M. McDonald, Guy B. Marks, Wei Min Li, Surinder S. Birring, Gang Wang, Peter G. Gibson. Treatable Traits in Elderly Asthmatics from the Australasian Severe Asthma Network: A Prospective Cohort Study. J Allergy Clin Immunol Pract. Jul 2021 1016/j.jaip.2021.03.042
  23. Natasha A Winter, Ling Qin, Peter G Gibson, Vanessa M McDonald, Katherine J Baines, Jack Faulkner, Tiffany Evans, Michael Fricker. Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma. Journal of Clinical Immunology. Aug 2021 1016/j.jaci.2021.01.033
  24. Couillard S, Laugerud A, Jabeen M, Ramakrishnan S, Melhorn J, Hinks T, Pavord I. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. Aug 2021 1136/thoraxjnl-2021-217325
  25. Jorge F Maspero, John Mark FitzGerald, Ian D Pavord, Megan S Rice, Jaman Maroni, Paul J Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Neil M H Graham, Ariel Teper, Megan Hardin. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. Aug 2021 1111/all.14872
  26. Gang Wang, Vanessa M McDonald. Contemporary Concise Review 2020: Asthma. Respirology. Aug 2021 1111/resp.14099
  27. Agustí A, Barnes N, Cruz AA, Gibson PG, Heaney LG, Inoue H, Leather D, Martinez FJ, McDonald VM, Oppenheimer J, Papi A, Pavord ID, Thomas M, Walker S, Yates L. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine. Aug 2021 1016/j.rmed.2021.106572
  28. Bokern MP, Robijn AL, Jensen ME, Barker D, Callaway L, Clifton V, Wark P, Giles W, Mattes J, Peek M, Attia J, Seeho S, Abbott A, Gibson PG, Murphy VE. Risk Factors Associated with Asthma Exacerbations During Pregnancy: protocol for a systematic review and meta-analysis. J Allergy Clin Immunol Pract. Aug 2021 (online ahead of print) 1186/s13643-022-01975-8
  29. Michael Fricker, Ling Qin, Stephany Sánchez-Ovando, Jodie L Simpson, Katherine J Baines, Carlos Riveros, Hayley A Scott, Lisa G Wood, Peter AB Wark, Nazanin Z Kermani, Kian Fan Chung, Peter G Gibson. An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype. Allergy Sept 2021 1111/all.15087
  30. Gibson PG, McDonald VM, Granchelli A, Olin JT. Asthma and Comorbid Conditions – Pulmonary Comorbidity. J Allergy Clin Immunol Pract. Sept 2021 1016/j.jaip.2021.08.028
  31. Lugogo N, Liu MC, Pavord I, Mitchell PD, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Bel EH. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. J Allergy Clin Immunol Pract. Sept 2021 1016/j.jaip.2021.05.024
  32. Busby J, Matthews JG, Chaudhuri R, Pavord ID, Hardman TC, Arron JR, Bradding P, Brightling CE, Choy DF, Cowan DC, Djukanovic R, Hanratty CE, Harrison TW, Holweg CT, Howarth PH, Fowler SJ, Lordan JL, Mansur AH, Menzies-Gow A, Niven RM, Robinson DS, Walker SM, Woodcock A, Heaney LG; investigators for the MRC Refractory Asthma Stratification Program. Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. Eur Respir J. Sept 2021 1183/13993003.00768-2021
  33. Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, Bosnic-Anticevich S, Harrington J, Hew M, Holland AE, Hopkins T, Jayaram L, Reddel H, Upham JW, Gibson PG, Bardin P. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. Respirology. Sept 2021 1111/resp.14147
  34. Risa Fukusho, Laurence Ruane, Debra Phyland, Joo Koh, Adriana Avram, Paul Leong,Martin MacDonald, Kenneth K Lau, Malcolm Baxter, Philip G Bardin.  A Multidisciplinary Team Clinic for Vocal Cord Dysfunction reduces Corticosteroid burst therapy. Journal of Allergy and Clinical Immunology: In Practice. Oct 2021 1016/j.jaip.2021.10.039
  35. Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB; Delphi Panel. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: In Practice. Nov 2021. 1016/j.jaip.2021.06.041
  36. Vertigan AE, Bone, SL., Gibson PG. The impact of functional laryngoscopy on the diagnosis of laryngeal hypersensitivity syndromes. Journal of Allergy and Clinical Immunology: In Practice. In Press 2021 1016/j.jaip.2021.10.017
  37. Leong P, Phyland DJ, Koo J, Baxter M, Bardin PG. Middle Airway Obstruction: Phenotyping Vocal Cord Dysfunction/Inducible Laryngeal Obstructions. Lancet Respiratory Medicine. Accepted 2021 1016/S2213-2600(21)00501-4
  38. Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB; Delphi Panel. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. J Allergy Clin Immunol Practice. Nov 2021 1016/j.jaip.2021.06.041
  39. Duszyk K, McLoughlin RF, Gibson PG, McDonald VM. The use of treatable traits to address COPD complexity and heterogeneity and to inform the care, Breathe. Dec 2021 1183/20734735.0118-2021
  40. Mallise CA, Murphy VE, Karayanidis F, Armstrong H, Whalen OM, Woolard AJ, Gibson PG, Mattes J, Collison A, Lane AE, Campbell LE. Parenting stress in mothers with asthma during the postpartum period. Journal of Asthma. Nov 2021 1080/02770903.2021.1993246
  41. Shaw DE, Heaney LG, Thomas M, Beasley R, Gibson PG, Pavord ID. Balancing the needs of the many and the few: where next for adult asthma guidelines? Lancet Respir Med. Jul 2021 1016/S2213-2600(21)00021-7
  42. Stubbs MA, Clark VL, Cheung MMY, Smith L, Saini B, Yorke J, Majellano EC, Gibson PG, McDonald VM. The Experience of Living with Severe Asthma, Depression & Anxiety: A Qualitative Art-Based Study, Journal of Asthma & Allergy. Dec 2021 2147/JAA.S328104
  43. Da Silva Sena CR, de Queiroz Andrade E, de Gouveia Belinelo P, Percival E, Prangemeier B, O’Donoghue C, Terry S, Burke T, Gunning W, Murphy VE, Robinson PD, Sly PD, Gibson PG, Collison AM, Mattes J. Higher exhaled nitric oxide at 6 weeks of age is associated with less bronchiolitis and wheeze for the 12 months of age, Thorax. Dec 2021 1136/thoraxjnl-2021-217299
  44. Duszyk K, McLoughlin RF, Gibson PG, McDonald VM. The use of treatable traits to address COPD complexity and heterogeneity and to inform the care, Breathe. Dec 2021 1183/20734735.0118-2021
  45. Stubbs MA, Clark VL, Cheung MMY, Smith L, Saini B, Yorke J, Majellano EC, Gibson PG, McDonald VM. The Experience of Living with Severe Asthma, Depression & Anxiety: A Qualitative Art-Based Study, Journal of Asthma & Allergy. Dec 2021 2147/JAA.S328104
  46. Shaw DE, Heaney LG, Thomas M, Beasley R, Gibson PG, Pavord ID. Balancing the needs of the many and the few: where next for adult asthma guidelines? Lancet Respir Med. Jul 2021 1016/S2213-2600(21)00021-7
  47. Mallise CA, Murphy VE, Karayanidis F, Armstrong H, Whalen OM, Woolard AJ, Gibson PG, Mattes J, Collison A, Lane AE, Campbell LE. Parenting stress in mothers with asthma during the postpartum period. Journal of Asthma. Nov 2021 1080/02770903.2021.1993246
  48. Da Silva Sena CR, de Queiroz Andrade E, de Gouveia Belinelo P, Percival E, Prangemeier B, O’Donoghue C, Terry S, Burke T, Gunning W, Murphy VE, Robinson PD, Sly PD, Gibson PG, Collison AM, Mattes J. Higher exhaled nitric oxide at 6 weeks of age is associated with less bronchiolitis and wheeze for the 12 months of age, Thorax. Dec 2021 1136/thoraxjnl-2021-217299
  49. Vertigan AE, Kapela SL, Birring SS, Gibson PG. Feasibility, and clinical utility of ambulatory cough monitoring in an outpatient clinical setting: a real-world retrospective evaluation, ERJ Open Research. Oct 2021 1183/23120541.00319-2021
  50. Foster PS, Barnes JL, Tay HL, Gibson PG. Transcriptomic drug-response gene signatures are informative for the stratification of patients for clinical trials, Journal of Allergy & Clinical Immunology. Jan 2021 1016/j.jaci.2021.09.021
  51. Williams C, Johnson B, Middleton PG, Backer V, Gibson PG, Hollis G, Coleman C. Family planning, pregnancy, and birth in women with lung conditions: a worldwide survey, ERJ Open Research. Dec 2021 1183/23120541.00357-2021
  52. Ali H, Brooks C, Crane J, Beasley R, Holgate S, Gibson P, Pattemore P, Tzeng YC, Stanley T, Pearce N, Douwes J. Enhanced airway sensory nerve reactivity in non-eosinophilic asthma, BMJ Journals 1136/bmjresp-2021-000974
  53. Harvey SM, Murphy VE, Whalen OM, Gibson PG, Jensen ME. Breastfeeding and wheeze-related outcomes in high-risk infants: A systematic review and meta-analysis, American Journal of Clinical Nutrition. Nov 2021 1093/ajcn/nqaa442
  54. de Gouveia Belinelo P, Collison AM, Murphy VE, Robinson PD, Jesson K, Hardaker K, de Queiroz Andrade E, Oldmeadow C, Martins Costa Gomes G, Sly PD, Usemann J, Appenzeller R, Gorlanova O, Fuchs O, Latzin P, Gibson PG, Frey U, Mattes J. Maternal asthma is associated with reduced lung function in male infants in a combined analysis of the BLT and BILD cohorts, Thorax. Oct 2021 1136/thoraxjnl-2020-215526
  55. Bondarenko J, Babic C, Burge AT, Holland AE. Home-based pulmonary rehabilitation: an implementation study using the RE-AIM framework, ERJ Open Research. May 2021 1183/23120541.00469-2020
  56. Shaw DE, Heaney LG, Thomas M, Beasley R, Gibson PG, Pavord ID, Balancing the needs of the many and the few: where next for adult asthma guidelines? The Lancet Respiratory Medicine. Jul 2021 1016/S2213-2600(21)00021-7
  57. O’Byrne PM, Reddel HK, Beasley R. The management of mild asthma, Euro Respiratory Journal. Apr 2021 1183/13993003.03051-2020
  58. Beasley R, Bruce P, Hatter L, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. A Proposed Revision of the Stepwise Treatment Algorithm in Asthma. American Journal of Respiratory and Critical Care Medicine. Jul 2021 1164/rccm.202101-0224LE
  59. Rogliani P, Beasley R, Cazzola M, Calzetta L. SMART for the treatment of asthma: A network meta-analysis of real-world evidence, Respiratory Medicine. Nov 2021 1016/j.rmed.2021.106611
  60. Reddel HK, Vestbo J, Agustí A, Anderson GP, Bansal AT, Beasley R, Bel EH, Janson C, Make B, Pavord ID, Price D, Rapsomaniki E, Karlsson N, Finch DK, Nuevo J, de Giorgio-Miller A, Alacqua M, Hughes R, Müllerová H, Gerhardsson de Verdier M, NOVELTY study investigators. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort, Euro Respiratory Journal. Sep 2021 1183/13993003.03927-2020
  61. Bush A, Dalziel SR, Byrnes CA, Hatter L, Beasley R. Has the time come to end use of the blue inhaler? Lancet Respir Med. Jun 2021 1016/S2213-2600(21)00185-5 Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, Williams M, McGregor AG, Eliahu A, Durk MR, Dengler HS, Zak M, Kenny JR, Wilson ME, Beasley R, Chen H. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial, Journal of Allergy & Clinical Immunology. Sep 2021 1016/j.jaci.2021.02.042 Lahham A, Holland AE. The Need for Expanding Pulmonary Rehabilitation Services, Life (Basel). Nov 2021 3390/life11111236
  62. Bush A, Pavord ID. Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease, Breathe. Sep 2021 1183/20734735.0053-2021 Malaguti C, Holland AE, McDonald CF, Mahal A, Alison JA, Hill CJ, Zanaboni P, O’Halloran P, Bondarenko J, Macdonald H, Barker K, Crute H, Mellerick C, Wageck B, Boursinos H, Lahham A, Nichols A, Czupryn P, Burge AT, Cox NS. Community Participation by People with Chronic Obstructive Pulmonary Disease, COPD Journal. Oct 2021 1080/15412555.2021.1966761
  63. Couillard S, Do WIH, Beasley R, Hinks TSC, Pavord ID. Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE), ERJ Open Research. Feb 2021 1183/23120541.00570-2021
  64. Burge AT, Rodrigues JC Jr, Abramson MJ, Cox NS, Bondarenko J, Webb E, Marceau T, Handley E, Macdonald H, Askin A, Calasans GASA, do Amaral DP, Dreger J, Dal Corso S, Holland AE. Application of the Modified Incremental Step Test for Pulmonary Rehabilitation, Physical Therapy & Rehabilitation Journal. May 2021 1093/ptj/pzab044
  65. José A, Holland AE, Selman JPR, de Camargo CO, Fonseca DS, Athanazio RA, Rached SZ, Cukier A, Stelmach R, Dal Corso S. Home-based pulmonary rehabilitation in people with bronchiectasis: a randomised controlled trial, ERJ Open Research. May 2021 1183/23120541.00021-2021
  66. Green ET, Cox NS, Holland AE. A Brief Intervention of Physical Activity Education and Counselling in Community Rehabilitation: A Feasibility Randomized Controlled Trial. Journal of Ageing & Physical Activity. Dec 2021 1123/japa.2021-0256
  67. Cox NS, Scrivener K, Holland AE, Jolliffe L, Wighton A, Nelson S, McCredie L, Lannin NA. A Brief Intervention to Support Implementation of Telerehabilitation by Community Rehabilitation Services During COVID-19: A Feasibility Study, American Congress of Rehabilitation Medicine. Apr 2021 1016/j.apmr.2020.12.007
  68. Malaguti C, Dal Corso S, Janjua S, Holland AE. Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease, Cochrane Library. Aug 2021 1002/14651858.CD013569.pub2
  69. Khor YH, Dudley KA, Herman D, Jacobs SS, Lederer DJ, Krishnan JA, Holland AE, Ruminjo JK, Thomson CC. Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung Disease, Annals of the American Thoracic Society. Sep 2021 1513/AnnalsATS.202102-165CME
  70. Dennett EJ, Janjua S, Stovold E, Harrison SL, McDonnell MJ, Holland AE. Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review, Cochrane Library. Jul 2021 1002/14651858.CD013384.pub2  
  71. Burge AT, Holland AE, McDonald CF, Hill CJ, Lee AL, Cox NS, Moore R, Nicolson C, O’Halloran P, Lahhama A, Gillies R, Mahald A. “Willingness to Pay”: The Value Attributed to Program Location by Pulmonary Rehabilitation Participants, COPD Journal. Jun 2021: 1080/15412555.2021.1924127
  72. AlQuran A, Batra M, Harry Susanto N, Holland AE, Davies JM, Erbas B, Lampugnani ER. Community Response to the Impact of Thunderstorm Asthma Using Smart Technology, Allergy & Rhinology. Apr 2021 1177/2152656721101072
  73. Smallwood N, Holland AE. Over-oxygenation in the acute hospital setting: an implementation failure in need of an implementation science solution, Internal Medicine Journal. May 2021 1111/imj.15326
  74. Cox NS, McDonald CF, Gleeson M, Wood L, Hall S, Hill C, Bondarenko J, Holland AE. Challenges of evaluating the effect of exercise training on salivary IgA in people with COPD The Clinical Respiratory Journal. Jun 2021 1111/crj.13337
  75. Kimmel LA, Burge A, Watterson D, Wolters C, Holland A, Reed M, Hunter P, Brookes B, Lee V, Leong R. Substituting inpatient rehabilitation beds for home-based multidisciplinary rehabilitation: A qualitative study of patient perceptions, Australasian Journal on Ageing. Sep 2021 1111/ajag.12883
  76. Bondarenko J, Hew M, Button B, Webb E, Jackson V, Clark R, Holland AE. Reliability of the breathing pattern assessment tool for in-person or remote assessment in people with asthma, Clinical & Experimental Allergy. Sep 2021 1111/cea.13856 Leong P, Bardin PG. The untreated treatable trait: Cardiovascular disease in COPD exacerbations, Respirology. May 2021 1111/resp.14036
  77. Bardin PG. Breathing-swallow dysfunction in COPD: How silent aspiration may be contributing to exacerbations, Official Journal of the Asian Pacific Society of Respirology. Dec 2021 1111/resp.14157
  78. Cvejic L, Guiney N, Lau KK, Finlay P, Hamza K, Leong P, MacDonald M, King PT, Bardin PG. Swallow patterns associated with aspiration in COPD: a prospective analysis, ERJ Open Research. Jul 2021 1183/23120541.00170-2021

2020

  1. Thomas, Dennis; McDonald, Vanessa M.; Simpson, Jodie L.; Smith, Amber; Gupta, Sachin; Majellano, Eleanor; Gibson, Peter G. Patterns of azithromycin use in obstructive airway diseases: a real-world observational study. Internal Medicine Journal https://onlinelibrary.wiley.com/doi/10.1111/imj.15216
  2. Thomas, Dennis; Harvey, Erin; McDonald, Vanessa M.; Stevens, Sean; Upham, John W.; Katelaris, Constance H.; Kritikos, Vicky; Gillman, Andrew; Harrington, John; Hew, Mark; Bardin, Philip; Peters, Matthew; Reynolds, Paul N.; Langton, David; Baraket, Melissa; Bowden, Jeffrey J.; Bowler, Simon; Chien, Jimmy; Chung, Li Ping; Farah, Claude S.; Grainge, Christopher; Jenkins, Christine; Katsoulotos, Gregory P.; Lee, Joy; Radhakrishna, Naghmeh; Reddel, Helen K.; Rimmer, Janet; Sivakumaran, Pathmanathan; Wark, Peter A. B.; Gibson, Peter G. Mepolizumab and oral corticosteroid stewardship – data from Australian Mepolizumab Registry The Journal of Allergy and Clinical Immunology: In Practice https://www.sciencedirect.com/science/article/pii/S2213219821001562?via%3Dihub
  3. McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J https://erj.ersjournals.com/content/55/3/1901509.long
  4. Sarah A Hiles, Paola D Urroz, Peter G Gibson, Adam Bogdanovs, Vanessa M McDonald. A feasibility randomised controlled trial of Novel Activity Management in severe ASthma – Tailored Exercise (NAMASTE): Yoga and Mindfulness. BMC Resp Open https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-021-01436-3
  5. Muhammad Rehan Sarwar, Vanessa Marie McDonald, Michael John Abramson, Eldho Paul, Johnson George. Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD. ERJ Open Research https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165376/
  6. Clark VL, Gibson PG, McDonald VM. The patients’ experience of severe asthma add-on pharmacotherapies; a qualitative descriptive study’. Journal of Asthma and Allergy. https://www.dovepress.com/the-patientsrsquo-experience-of-severe-asthma-add-on-pharmacotherapies-peer-reviewed-fulltext-article-JAA
  7. Natasha A Winter, Ling Qin, Peter G Gibson, Vanessa M McDonald, Katherine J Baines, Jack Faulkner, Tiffany Evans, Michael Fricker. Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma. Journal of Clinical Immunology https://www.jacionline.org/article/S0091-6749(21)00222-0/fulltext
  8. Vanessa M McDonald, Paola D Urroz, Marika Bajc, Natalie Rutherford, Bree Brooker, Peter G Gibson. Imaging for Precision Medicine: Can V-P SPECT measure Mepolizumab Response in Asthma? Respirol Case Rep https://onlinelibrary.wiley.com/doi/full/10.1002/rcr2.717
  9. Eleanor C Majellano, Vanessa L Clark, Juliet M Foster, Peter G Gibson, Vanessa M McDonald. It’s like being on a roller coaster: The burden of caring for people with severe asthma. ERJ Open Research. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039902/
  10. Michael Fricker, Vanessa M. McDonald, Natasha A. Winter, Katherine J. Baines, Peter A.B. Wark, Jodie L. Simpson, Peter G. Gibson. Molecular markers of type 2 airway inflammation are elevated in eosinophilic severe asthma, but not in eosinophilic COPD. Allergy. https://onlinelibrary.wiley.com/doi/10.1111/all.14741
  11. Patricia D Freitas, Rafaela F Xavier, Vanessa M McDonald, Peter G Gibson, Laura Cordova-Rivera, Karina C Furlanetto, Joice M de Oliveira, Regina M Carvalho-Pinto, Alberto Cukier, Rafael Stelmach, Celso R F Carvalho. Identification of asthma phenotypes based on extrapulmonary traits; physical activity, psychosocial distress and obesity. Eur Respir J. https://erj.ersjournals.com/content/57/1/2000240.long
  12. Xin Zhang, Li Zhang, Rui Liang, Vanessa M McDonald, Hong Ping Zhang, He Yu, Zong An Liang, Lei Wang, Guy B Marks, Wei Min Li, Gang Wang, Peter G Gibson. Clinical phenotypes of patients hospitalized for an asthma exacerbation: prognostic implications. J Allergy Clin Immunol Pract. https://www.sciencedirect.com/science/article/pii/S2213219820310096?via%3Dihub
  13. Natasha Winter, Peter G Gibson, Michael Fricker, Jodie L Simpson, Peter AB Wark, Vanessa M McDonald. Hemopexin: a novel anti-inflammatory diagnostic marker in chronic airway disease. Allergy Asthma Immunol Res. https://e-aair.org/DOIx.php?id=10.4168/aair.2021.13.3.450
  14. Feng M, Zhang X, Wu WW, Chen ZH, Oliver BG, McDonald VM, Zhang HP, Xie M, Qin L, Zhang J, Wang L, Li WM, Wang G, Gibson PG. Clinical and Inflammatory Features of Exacerbation-Prone Asthma: A Cross-Sectional Study Using Multidimensional Assessment. Respiration. https://www.karger.com/Article/Abstract/510793
  15. Vanessa L Clark, Peter G Gibson, Vanessa M McDonald. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Research. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005593/
  16. Sarah A. Hiles, Peter G. Gibson, Alvar Agusti, Vanessa M. McDonald. Treatable Traits That Predict Health Status and Treatment Response in Airway Disease. J Allergy Clin Immunol Pract. https://www.sciencedirect.com/science/article/pii/S2213219820310965?via%3Dihub
  17. Shukla SD, Taylor SL, Gibson PG, Barker D, Upham JW, Yang IA, Reynolds PN, Hodge S, James AL, Rogers GB, Simpson JL. Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. Thorax. https://thorax.bmj.com/content/76/7/733.long
  18. Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. https://www.sciencedirect.com/science/article/pii/S2213219821000672
  19. Murphy VE, Jensen ME, Robijn AL, Wright TK, Mattes J, Collison A, Gibson PG. How Maternal BMI Modifies the Impact of Personalized Asthma Management in Pregnancy. J Allergy Clin Immunol Pract https://www.sciencedirect.com/science/article/pii/S2213219819306063?via%3Dihub
  20. LauraCordova-Rivera, Paul A.Gardiner, Peter G.Gibson, Elisabeth A.H.Winkler, Paola D.Urroz, Vanessa M.McDonald. Sedentary time in people with obstructive airway diseases. Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S0954611121000731
  21. Sarah A Hiles, Peter G Gibson, Vanessa M McDonald. Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma–COPD overlap. https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.13841
  22. Wen Wen Wu, Xin Zhang, Min Li, Ying Liu, Zhi Hong Chen, Min Xie, Shu Zhen Zhao, Gang Wang, Hong Ping Zhang, Ting Wang, Ling Qin, Lei Wang, Brian G. Oliver, Hua Jing Wan, Jie Zhang, Vanessa M. McDonald, Guy B. Marks, Wei Min Li, Surinder S. Birring, Gang Wang, Peter G. Gibson. Treatable Traits in Elderly Asthmatics from the Australasian Severe Asthma Network: A Prospective Cohort Study JACI in Practice. https://www.sciencedirect.com/science/article/pii/S2213219821003871?via%3Dihub
  23. Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology. https://onlinelibrary.wiley.com/doi/10.1111/resp.13730
  24. Erin S Harvey , David Langton , Constance Katelaris, Sean Stevens , Claude S Farah, Andrew Gillman , John Harrington, Mark Hew , Vicky Kritikos, Naghmeh Radhakrishna , Philip Bardin , Matthew Peters , Paul N Reynolds , John W Upham , Melissa Baraket , Simon Bowler , Jeffrey Bowden, Jimmy Chien , Li Ping Chung, Christopher Grainge, Christine Jenkins , Gregory P Katsoulotos, Joy Lee , Vanessa M McDonald, Helen K Reddel , Janet Rimmer , Peter A B Wark, Peter G Gibson. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. https://erj.ersjournals.com/content/55/5/1902420.long
  25. Hew M, McDonald VM, Bardin PG, Chung LP, Farah CS, Barnard A, Cooper MS, Gibson PG, Upham JW. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. https://onlinelibrary.wiley.com/doi/10.5694/mja2.50758
  26. O’Neill C, Gibson PG, Heaney L, Upham JW, Yang I, Reynolds P, Hodge S, Jenkins C, Peters M, Marks GB, James AL, Simpson J. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Eur Respir J. https://erj.ersjournals.com/content/57/2/2002436.long